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Caffeine has been used for many years and is one of the most extensively consumed active food 
ingredient throughout the world. Caffeine has been broadly studied in a variety of areas 
regarding human health and performance. Various reports have shown that consumption of 
coffee or caffeine containing drinks are associated with the reduction of type 2 diabetes related 
symptoms, promotes weight loss and acts as an antioxidant. However, the fundamental 
mechanisms have not been understood. Therefore, the main objective of this study was to 
investigate the mechanisms behind the anti-diabetic effects of caffeine. Various in vitro, ex vivo 
and in vivo models were used to achieve this objective. The results of this study showed that 
caffeine possessed strong antioxidant potential and was able to inhibit key enzymes linked to 
type 2 diabetes in vitro. The results of this study further demonstrate that caffeine can modulate 
T2D-induced oxidative stress in various organs in vivo. Caffeine was able to reduce small 
intestinal glucose absorption, increase muscle glucose uptake ex vivo, improve pancreatic β-
cell function and stimulate insulin secretions in an animal model of type 2 diabetes. Pancreatic 
histopathology showed that caffeine ameliorated T2D-induced pancreatic β-cell destruction and 
their functions at the end of the study. Data of this study suggest that caffeine can be used an 
anti-diabetic supplement in anti-diabetic foods and food products, however, a safer effective 
dose still needs to be identified. Hence, further studies are warranted in experimental animals 
and humans to determine the most effective and safer dose of caffeine for achieving its 





















Diabetes mellitus (DM) is a chronic condition that occurs when there are raised levels of 
glucose in the blood because the body cannot produce any or enough insulin or use insulin 
effectively (DeFronzo et al., 2015). Insulin is a hormone produced in the pancreatic beta-cells 
of the body, and it is responsible for transporting glucose from the bloodstream into the body’s 
cells where the glucose is converted into energy. The deficiency of insulin or the incapability 
of the cells to react to insulin results in high levels of blood glucose. Hyperglycemia can cause 
impairment to several body organs, resulting in the development of various health 
complications such as cardiovascular disease, neuropathy, nephropathy and eye disease, 
leading to retinopathy and blindness.  
 
Figure 1.1:  Roles of insulin and glucagon in blood glucose homeostasis (IDF Diabetes Atlas, 
2017) 
1.1. Prevalence of diabetes 
According to International Diabetes Federation (IDF), the incidence of diabetes estimated for 
the years 2017 and 2045 are 87% to 91%. Approximately 425 million people worldwide are 
estimated to have diabetes of which 79% live in the low and middle-income countries. IDF 





Globally, 727 billion USD are being spent annually by individuals with diabetes as their 
healthcare expenditure.  
 
Figure 1.2: Estimated total number of adults (20-79 years) living with diabetes, 2017 (IDF 
Diabetes Atlas, 2017) 
Table 1.1: People living with diabetes (20-79 years) who are undiagnosed in the different 
regions of the world (IDF Diabetes Atlas, 2017). 
Rank IDF Region  Proportion 
undiagnosed 
Number of people with 
undiagnosed diabetes 
1 Africa 69.2% 10.7 million 
2 South-East Asia 57.6% 47.2 million 
3 Western Pacific 54.1% 85.9 million 
4 Middle East and North Africa 49.0% 19.0 million 
5 South and Central America 40.0% 10.4 million 
6 Europe 37.9% 22.0 million 





It has been estimated that globally as many as 212.4 million people with diabetes are not aware 
of their illness. Since half of the people with diabetes are undiagnosed, it is essential to monitor, 
diagnose and offer suitable care to subjects with diabetes. People with undiagnosed diabetes 
are subject to higher usage of healthcare services in comparison to people without diabetes, 
and therefore more likely to experience higher healthcare expenditures (IDF Diabetes Atlas, 
2017).  
1.1.1. Type 1 diabetes 
Type 1 diabetes (T1D) is triggered when the body’s immune system attacks the insulin-
producing beta cells in the islets of the pancreas gland. As a result, the body produces little or 
no insulin. Various factors such as genetic predisposition and environmental factors such as 
viral infection, toxins or some dietary factors have been associated with type 1 diabetes 
(Hinneburg et al., 2006). The disease can progress at any age, but type 1 diabetes transpires 
more commonly in children and adolescents. People with type 1 diabetes require regular insulin 
injections to maintain the glucose level at a physiologically safer range. However, the 
prevalence of type 1 diabetes is significantly lower than type 2 diabetes. 
1.1.2. Type 2 diabetes 
Type 2 diabetes (T2D) is the most common type of diabetes, accounting for around 90% of all 
cases of diabetes (Holman et al., 2015). In type 2 diabetes, hyperglycemia is the consequence 
of insufficient production of insulin and the inability of the body to respond fully to insulin. 
Factors such as consumption of unhealthy diet, high simple carbohydrate and high fat diet, 
obesity, physical inactivity, increasing age as well as ethnicity and family history are 
considered as the major causal factors for the development of type 2 diabetes.  Common risk 
elements mentioned above give rise to an oxidative stress setting, which could modify insulin 
sensitivity either by increasing insulin resistance or by impairing glucose tolerance (Rains and 
Jain, 2011). Oxidative stress is one of the major causal factors for type 2 diabetes. 
1.2. Oxidative stress 
Oxidative stress can be defined as a state of imbalance between free radicals (superoxide or 
hydroxyl radicals) and antioxidants like superoxide dismutase (SOD), catalases and glutathione 
peroxidases (GPX) and so on (Styskal et al., 2012). Under oxidative stress condition, free 
radicals that are not reduced or removed from the cellular environment can cause damage to 
nucleic acids, lipids and proteins (Mathews et al., 2000). Factors such as obesity, 





elevated reactive oxygen species (ROS) production or reduced antioxidant defense (Mathews 
et al., 2000). Diabetic subjects show increase in ROS generation. Free radicals are uncharged 
molecules having unpaired electrons which react with biomolecules owing to decreased 
enzymatic anti-oxidants activity. Antioxidants can react with free radicals by donating an 
electron, thereby stabilizing it. Antioxidant components have attracted great attention because 
of their capability to scavenge free radicals by inhibiting oxidation (Perez et al., 2009).   
Most living organisms possess proficient enzymatic and non-enzymatic defense systems 
against excess production of ROS and reactive nitrogen species (RNS). However, different 
external factors decrease the capability of such endogenous antioxidant defenses, resulting in 
disturbances of the redox equilibrium that is established in healthy conditions. Increased levels 
of free radicals result in impairment of cellular proteins, membrane lipids and nucleic acids, 
which will ultimately result in death of the cells in the body (King and Loeken, 2004).  
Hyperglycemia is also found to promote lipid peroxidation of low density lipoprotein (LDL) 
by a superoxide-dependent pathway resulting in the generation of free radicals (Maritim et al., 
2002). 
1.2.1. Oxidative stress and the antioxidant defense system 
Oxidative stress is defined as a disproportion of elements that produce  ROS such as superoxide 
or hydroxyl radicals and the enzymes that defend the cells from these pro-oxidants are 
superoxide dismutases, catalase, and glutathione peroxidases (Pérez-Matute et al., 2009). 
Figure 1.3: Schematic diagram of pathways that contribute to oxidative stress and enzymes 





Mitochondria are the basis of most cellular ROS, precisely superoxide radicals. The reactions 
that produce ATP in the mitochondria involve electrons from reduced substrates to be delivered 
along the complexes of the electron transport chain (Pérez-Matute et al., 2009). In the 
occurrence of molecular oxygen, electrons that seep from this process react and generate 
superoxide. Superoxide anions are important mediators in many oxidative chain reactions and 
they are also precursors to many other ROS (Halliwell and Gutteridge, 2015). Other important 
intracellular causes of ROS production include NADPH oxidases (which generate superoxide), 
nitric oxide synthases (nitric oxide), and lipoxygenases (fatty acid hydroperoxides). Also, 
specific cells can stimulate an oxidative environment. For example, macrophages can yield 
oxidative stress as part of the inflammatory response (Federico et al., 2007). Some ROS, such 
as superoxide and hydrogen peroxide are essential in supporting natural cellular function and 
for the regulation of intracellular signaling (Pérez-Matute et al., 2009). However, excess ROS 
production (or reduced ROS regulation) could cause impairment of cells and subsequently lead 
to macromolecular damage, dysfunction, and death (Hartley et al., 1997).  
Oxidation of DNA has been known to be involved in cellular senescence, apoptosis, and the 
progression of cancerous cell phenotypes. On the other hand, oxidation of lipids is the basis for 
changes in structure and fluidity of cellular and organelle membranes that are harmful to 
cellular processes and functions (Esterbauer et al., 1993). This disturbs the normal cellular 
functioning, further increasing cellular ROS concentrations.  In addition, oxidation of lipids 
might form lipid radical species that could possibly cause impairment of many cellular 
macromolecules. For example, lipid peroxides like malondialdehyde (MDA) and 4- 
hydroxynonenal (4HNE) can react with both DNA and proteins (Hartley et al., 1997).  
Aerobic organisms have developed a composite antioxidant system comprising of general 
antioxidants (that is, those that reduce oxidative stress by removal of ROS) and specialized 
enzymes that can repair some forms of oxidation within cellular macromolecules (Halliwell 
and Gutteridge, 2015).  These complex processes were developed, since oxidative stress could 
cause lethal effects even under normal physiological conditions. There are several enzymes 
involved in the antioxidant defense system and they take part in special roles in defense and 
repair. Superoxide dismutase (SOD) decreases superoxide levels in the cell; these enzymes 
catalyze the conversion of the superoxide radical to molecular oxygen and hydrogen peroxide. 
They are one of the first lines of defense against superoxide radicals produced by the 
mitochondria during cellular respiration and against superoxide produced by other cellular 





Peroxides, including those generated by SOD are converted into water in the cell primarily by 
catalase, glutathione peroxidases, and peroxiredoxins. Catalase (CAT) is ubiquitously 
expressed among mammalian tissues and is primarily located in the peroxisomes. The primary 
catalytic function of catalase is the decomposition of hydrogen peroxide to oxygen and water 
(Halliwell and Gutteridge, 2015). In general, glutathione peroxidases (GPx) can reduce 
peroxides (including hydrogen peroxide and lipid hydroperoxides) to less toxic forms including 
water and alcohols. In addition, thioredoxins (Trx) catalyze reduction of disulfide bonds in 
multiple substrate proteins (Halliwell and Gutteridge, 2015). Through this reaction, Trxs act as 
antioxidants by detoxifying peroxides through peroxiredoxins and by reducing protein 
disulfides and methionine sulfoxides, either directly or through the actions of other 
oxidoreductases (Powis and Montfront, 2001).   
1.2.2. Oxidative stress and insulin resistance 
Excessive oxidative stress is detrimental to insulin signaling. There are now several lines of 
evidence from both model organisms and clinical studies that identified a strong correlation 
between insulin resistance, T2DM, metabolic syndrome and oxidative stress. Hyperglycemia 
itself can cause an increase in oxidative stress as the level of lipid peroxidation in erythrocytes 
was found to be directly proportional to the glucose concentrations in vitro and to blood glucose 
concentrations in diabetic patients (Rain and Jain, 2011). Diabetes is associated with reduced 
levels of components of the antioxidant defense system including GSH, vitamin E, and vitamin 
C (Rains and Jain, 2011). Diabetes and insulin resistance are also associated with reduction in 
total antioxidant activity, SOD, GPx, and glutathione reductase activity. Hyperglycemia may 
be a significant factor in the down regulation of antioxidant activity. 
Oxidative stress could lead to insulin resistance by stimulating the expression of several 
proinflammatory cytokines (Perez et al., 2009). Several research groups have found an 
association between increased carbonylation and nitrosylation of proteins in insulin-sensitive 
tissues and obese or insulin-resistant phenotypes (Perez et al., 2009).  Oxidation of specific 
proteins in vitro has a clear detrimental effect on their function. And there is a strong correlation 
between increasing oxidative stress and diminished protein folding and function in different 
animal models (Perez et al., 2009). It might be predicted that oxidation of proteins is important 
for insulin signaling which could potentially affect their function in propagation of insulin-





In vitro studies have shown that oxidative stress can impair the ability of insulin receptor to 
correctly bind with insulin (Fridlyand and Philipson, 2006). Oxidative stress can also alter the 
ability of insulin signaling proteins to redistribute to correct subcellular locations that are 
necessary for efficient transduction of signals. From a therapeutic standpoint, it is evident that 
reduced oxidative stress may be beneficial in the prevention and treatment of insulin resistance. 
Insulin resistance significantly affects the carbohydrate metabolism as well as blood glucose 
regulation.  
1.3. Carbohydrate metabolism and blood glucose regulation 
One of the key dietary sources of glucose in the human body is carbohydrates from starch, 
which is also a product of starch hydrolysis. Carbohydrates have an influential impact on 
postprandial blood glucose levels after being absorbed in the small intestine (Dhital et al., 
2013). The major link among diabetes, obesity and other metabolic disorders are correlated to 
the rate and extent of carbohydrate (CHO) digestion and the absorption of glucose (Dhital et 
al., 2013). 
The CHO is hydrolyzed into oligosaccharides, disaccharides and monosaccharides by CHO 
hydrolyzing enzymes such as alpha amylase (AA) and alpha glucosidase (AG). Alpha amylase 
consists of a group of calcium dependent enzymes that catalyzes the random break down of 
amylose and amylopectin units in starch to yield smaller CHO units like maltotriose, maltose 
and glucose (Qian et al., 1997). In humans, they are found in several tissues, but are mostly 
present in the saliva and pancreatic juice (Qian et al., 1997). 
Alpha glucosidase catalyzes the release of alpha glucose from the reducing terminal end of 
alpha glycosyl residue-possessing substrates (Okuyama et al., 2005). In human, they are 
present in the intestinal mucosa as two membrane bounded protein complexes (maltase-
glucoamylase and sucrase-isomaltase), which catalyzes from the reducing, end the hydrolysis 
of α-1,4-glycosidic linkages resulting from AA starch degradation to form free glucose (Dhital 
et al., 2013). 
After the starch and carbohydrates have been broken down into glucose, it is thereafter 
absorbed into the blood by the wall of the duodenum. The body consists of correct mechanisms 
to confirm physiological blood glucose homeostasis. When glucose is not required, it is 
removed from the blood by the conversion of the excess glucose to glycogen, which is then 
stored in the liver. When the body needs energy or when the blood glucose levels have 





into the bloodstream. (Mathews et al., 2000). Glucagon and insulin are the two major hormones 
in the body that work consistently to regulate and maintain physiological blood glucose 
homeostasis. 
When the blood glucose levels are low, the alpha cells found in the pancreas produces 
glucagon.  Glucagon hormone causes the cAMP dependent activation of glycogen 
phosphorylase, which then catalyzes the phosphorylytic breakdown of glycogen to release 
glucose-6-phosphate into the blood (Mathews et al., 2000). When the glycogen levels are low, 
the glucagon hormone stimulates gluconeogenesis. Insulin is released from the beta-cells of the 
pancreas, when the glucose levels in the blood rises due to the breakdown of glycogen or 
intestinal glucose absorption, and this promotes cell glucose uptake and by the cell membrane 
glucose transporter type 4 (GLUT4); glycolysis; inhibition of glucagon secretion by alpha cells; 
and also signals the activation of glycogen synthase that catalyzes the conversion of glucose to 
glycogen, thus normalizing blood glucose level (Mathews et al., 2000).  
Insulin resistance is a disorder in glucose metabolism and homeostasis that can give rise to 
hyperglycemic conditions in T2D. 
1.4. Insulin and normal insulin signaling 
Insulin is an important hormone that plays a role in part in the growth and development of 
tissues and the control of glucose equilibrium in the body (Rains and Jain., 2011). It is released 
by pancreatic β-cells and the prime role of this hormone is to control glucose homeostasis by 
the stimulation of glucose transport into muscle and adipose cells, while reducing hepatic 
glucose production via gluconeogenesis and glycogenolysis (Rains and Jain, 2011). Another 
important role of insulin, is that it can regulate lipid metabolism by increasing lipid synthesis 
in liver and fat cells while inhibiting lipolysis. Insulin is also essential for the uptake of amino 
acids and protein synthesis (Rains and Jain, 2011). However, insulin resistance one of the two 
major pathogenesis of type 2 diabetes. 
1.4.1. Insulin resistance 
Insulin resistance is associated with the onset and development of T2D. It is linked with various 
factors such as genetic and environmental factors. Nonetheless, environmental factors like lack 
of exercise, aging, high carbohydrate and high fat diet and obesity are the most impelling 
factors which can contribute to the progression and development of insulin resistance (Kahn, 
2003). Insulin resistance transpires when affected cells such as myocytes, adipocytes and 





insensitive to insulin and therefore the release of insulin hormone into the blood does not 
efficiently regularize the level of blood glucose (Kahn, 2003). 
Insulin is also significant in the regulation of body fat metabolism. It is critical for promoting 
uptake of circulating free fatty acid (FFA); differentiation and maturation of adipocytes; 
lipogenesis; and inhibition of lipolysis (Kahn, 2003). Consequently, a deficiency in fat 
metabolism, abnormally high plasma FFA and triacylglyceride and irregularly low plasma high 
density lipoprotein levels can transpire during insulin resistance, which can influence an insulin 
resistant patient to obesity, metabolic syndrome and other complications related to diabetes 
(Rabol et al., 2011). Many cellular studies reported and shown that under oxidative stress 
conditions, insulin signaling is impaired, which results in insulin resistance. This could be 
investigated by measuring glucose uptake (Rains and Jain, 2011).  
1.5. Intestinal absorption of glucose 
Persistent hyperglycemia throughout type 2 diabetes is intensely influenced by the degree of 
intestinal absorption of glucose resulting from digestible carbohydrate like starch and sucrose 
consequently, by limiting the rate of postprandial intestinal glucose absorption will transform 
into significant glycemic control (Hanhineva et al, 2010). 
Intestinal absorption of glucose is mediated by active transport via sodium-dependent glucose 
transporter (SGLT1) and by facilitated sodium-independent transport via the glucose 
transporter GLUT2 (Hanhineva et al, 2010). The reduction of late postprandial glycemia may 
be explained by an elevated insulin response following stimulation of pancreatic beta-cells 
rather than by retarded absorption of glucose (Hanhineva et al, 2010).  
In the recent years, type 2 diabetic patients are always trying to reduce their blood glucose 
levels not only by taking oral hypoglycemic drugs but also by using various functional and 
medicinal foods and food supplements, caffeine is one of them in our regular food list. 
1.6. Caffeine  
Caffeine (1, 3, 7-trimethylxanthine) is an alkaloid belonging to the methylxanthine family. It 
is naturally present in the seeds, leaves and fruits of more than 63 plant species (Del Coso et 
al., 2012; Geethavani et al., 2014). Approximately 80% of the world population consumes at 
least one caffeinated product daily (Kumar et al., 2018). Caffeine consumption is most 
common through beverages such as coffee (71%), soft drinks (16%) and tea (12%) (Nehlig, 





of more than 300 mg/day in leading countries like Denmark, Finland and Brazil (Kumar et al., 
2018).  
 
1.6.1. Natural sources of caffeine  
The most important sources of caffeine are coffee (Coffea spp.), tea (Camellia sinensis), 
guarana (Paullinia cupana), kola nuts (Cola vera), cocoa (Theobroma cacao) and caffeinated 
soft drinks which includes energy drinks (Fulgoni et al., 2015).  Coffee is cultivated globally, 
and the key producers are Brazil, Vietnam, Indonesia, Columbia and Ethiopia (Pohlan and 
Janssens, 2010). Whereas, tea is the most extensively ingested beverage after water and 
contains caffeine as an active dietary constituent. Guarana, a product of a climbing shrub 
(Paullinia cupana) is native to Brazil, Bolivia, Peru, Uruguay and Venezuela and being rich in 
caffeine, guarana and kola nuts relish great attractiveness as they serve as a stimulant 
(Muhammad and Fatima, 2014). Several caffeinated products are available in the market which 
is attracting consumer’s attention. Caffeine is utilized for the preparation of many coffee and 
coffee-based beverages, tea, energy drinks and cocoa products. 
Caffeine is absorbed in the body thereafter it reaches the brain within five minutes after 
ingestion (Baribeau et al., 2014) and is also eliminated with an average half-life of five hours 
from the body (Heckman et al., 2010). Once ingested, caffeine is rapidly absorbed from the 
gastrointestinal tract into the bloodstream and becomes metabolized in the liver (Heckman et 
al., 2010). Caffeine is metabolized by the liver to form 3 major metabolites, which are 3,7-
dimethylxanthine, 1,7-dimethylxanthine, and 1,3-dimethylxanthine. Once absorbed, caffeine 
employs many physiological actions to various organs in the body.  
1.6.2. Beneficial effects of caffeine  
Caffeine has many pharmacological as well as physiological effects on the human body. Some 
of these effects are on respiratory (Franco et al., 2013), cardiovascular (Butt and Sultan, 2013), 
gastrointestinal and the central nervous system (Baribeau, 2014). Caffeine is commonly 
consumed for its role to work as a mild nervous chemical stimulant towards drowsiness and 
fatigue (Wolde, 2014). It is used as an adjuvant analgesic in combination with drugs like 
acetaminophen, aspirin and ibuprofen (Migliardi et al., 1994). 
The various beneficial effects of it include the reduced risk of diabetes by exerting positive 
effects on glucose metabolism and liver injury (Wolde, 2014), It helps to reduce the risk of 





psychomotor performance and improves overall immune response (Wolde, 2014). Caffeine 
offers diverse benefits including its role in increasing alertness, vigilance, mood as well as 
psychomotor and cognitive performance (Glade, 2010).  
1.6.3. Caffeine and its role as an antioxidant 
Various biochemical reactions in our body create ROS essentially comprising free radicals that 
have detrimental effects on biomolecules. Oxidative stress results when they are not effectively 
neutralized by the antioxidant defense systems. Polyunsaturated fatty acids have become a 
central area of interest in the biochemistry of oxidative stress caused by ROS (Sies, 1986). 
These fatty acids are mainly present in the phospholipids of biological membranes and their 
unspecific oxidation by ROS known as lipid peroxidation is a radical mediated pathway and a 
highly damaging event. It generates toxic byproducts such as 4-hydroxy- nonanal known to 
alter other biomolecules in the cell (Buettner, 1993).  One of the areas which have attracted a 
great deal of attention is the possible role of antioxidants in the control of oxidative damage. 
Therefore, it helps to prevent different diseases by protecting cells in the body against oxidative 
damage (Wolde, 2014) and raise the overall immunity of a person. Studies have shown that 
caffeine, at millimolar concentrations, is a potent antioxidant capable of preventing lipid 
peroxidation. These reports have suggested that the ability of caffeine to inhibit lipid 
peroxidation is similar to glutathione and significantly greater than that of ascorbic acid.  
1.6.4. Caffeine and its role in diabetes 
Several reports have demonstrated that the consumption of Coffee (a source of caffeine) is 
linked with a lower risk of type 2 diabetes mellitus (Heckman et al., 2010). Caffeine intake has 
been found to decrease one’s sensitivity towards insulin, leading to decreased storage of 
glucose (Butt and Sultan, 2011). Caffeine exerts positive effects on glucose metabolism 
through increased uncoupling protein expression and lipid oxidation leading to decreased 
glucose storage capacity which in turn reduces the degree of diabetes mellitus (Butt and Sultan, 
2011). A report shows that high caffeine intake is related with reduction in diabetes risk. 
(Wolde, 2014). 
It is also reported that caffeine improved peripheral glucose utilization with insulin sensitivity, 
improved insulin secretion and increased glucokinase expression as well as increased 
pancreatic β-cell mass by increased proliferation in diabetic rats (Park et al., 2007). Caffeine 





neuroprotective effects in STZ-induced diabetic rats by preventing synaptic degradation and 
astrogliosis in the brain which is caused by hyperglycemia (Duarte et al., 2009). 
It is postulated that caffeine has ability to inhibit adenosine monophosphate phosphodiesterase 
(cAMP-PDE) which leads to an increase in intracellular cAMP concentrations (Horrigan et al., 
2008). Intracellular accumulation of cAMP enhances glucose regulation in the pancreatic β-
cells and liver (Horrigan et al., 2008).  by activating the cAMP-responding element-binding 
protein which results in an increase in IRS-2 expression. This leads to an improved glucose 
homeostasis by enhancing insulin and insulin-like growth factor 1(IGF-1) signaling in the 
islets. This insulin signaling process occurs through the activation of tyrosine phosphorylation 
which activates Akt that is located downstream of IRS-2 (Jhala et al., 2003).  
In 2008, Kagami et al. observed that caffeine has a potent pancreatic β-cell protecting effect in 
rat and they found that the pancreatic insulin content was significantly recovered by caffeine 
pre-treatment at 100 mg/kg body weight (Kagami et al., 2008).  
 
1.6.5. Caffeine and weight management 
Caffeine supplementation has been recently considered as an effective means of weight 
management. It increases metabolism and thus plays an effective role in weight management 
(Heckman et al., 2010). Oxygen consumption and fat oxidation was found to increase after 
caffeine consumption which suggests its role in weight loss (Greenway, 2001). Another report 
showed that caffeine consumption, as contained in green tea, has been associated with weight 
reduction (Wedick, 2011). Energy balance is the main determinant of weight regulation. 
Research on caffeine has confirmed its role in increasing metabolic rate, energy expenditure 
(EE), lipid oxidation, and lipolytic and thermogenic activities; all favorable components 















1.7. Rationale of the study 
In addition to lifestyle modifications, there are several therapeutic approaches used in the 
management of T2D and related disorders like oxidative stress.  These include synthetic anti-
diabetic drugs like sulphonylureas (glibenclamide), glucosidase inhibitors (acarbose) and 
biguanide (metformin) as well as natural and synthetic anti-oxidants. However, most synthetic 
oral hypoglycemic agents have reportedly shown characteristic profiles of serious side effects 
such as hypoglycemia, weight gain, gastrointestinal discomfort and nausea, liver and heart 
failures and diarrhea. Hence, there has been a need to explore other therapeutic agents to 
replace or synergistically complement the existing ones. 
 
1.8. Aim 
To investigate the anti-diabetic mechanisms of caffeine in a type 2 diabetes model of rats.  
 
1.9. Objectives of the study 
➢ To investigate the in vitro and ex vivo anti-oxidative activities of caffeine. 
➢ To investigate the inhibitory effect of caffeine on α-amylase, α-glucosidase and 
pancreatic lipase activities. 
➢ To investigate the effect of caffeine on intestinal glucose absorption in isolated rat 
jejunum and muscle glucose uptake in rat psoas muscle. 
➢ To investigate the in vivo anti-oxidative and anti-diabetic mechanisms of caffeine in a 










































2.1. Chemicals and reagents 
Ascorbic acid, calcium chloride di-hydrate, caffeine, dinitrosalicylic acid (DNS), disodium 
EDTA, ferric chloride, ferrous sulphate heptahydrate, Griess reagent, hydrogen peroxide, 
mono-basic mono-basic potassium phosphate, sodium chloride, sodium bicarbonate, sodium 
citrate, sodium hydroxide, sodium hydrogen carbonate, sodium phosphate, sodium 
nitroprusside, starch, sulphuric acid, trichloroacetic acid, reduced glutathione and 
thiobarbituric acid were purchased from Merck Chemical Company, Durban, South Africa. 
Acarbose, ammonium molybdate tetrahydrate, citric acid, 2 deoxy-D-ribose, di-basic sodium 
phosphate, diethylenetriaminepentaacetic acid (DETAPAC), 5,5′-dithiobisnitrobenzoic acid 
(DTNB), 1,1-diphenyl-2-picrylhydrazyl radical (DPPH), gallic acid, 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (trolox), 6-hydroxydopamine, p-nitrophenyl-α-D-
glucopyranoside (pNPG), 3-(N-morpholino) propanesulfonic acid (MOPS) p-nitrophenol, 
porcine pancreatic amylase, potassium ferricyanide, sodium acetate, streptozotocin and yeast 
α-glucosidase, were obtained from Sigma-Aldrich through Capital Lab Supplies, New 
Germany, South Africa.  Glucose and fructose were bought from Associated Chemical 
Enterprise (ACE), South Africa, while metformin was purchased from a local pharmacy 
(Pharmed) in Durban, South Africa. 
An ultra-sensitive rat insulin ELISA kit was purchased from Mercodia AB, Uppsala, Sweden. 
Reagents to test the other serum parameters were bought from Labtest Diagnostics (Lagoa 
Santa, Brazil) purchased through Replamed Company Ltd., Centurion, South Africa.  
 
2.2. Equipment  
 
Shimadzu UV mini 1240 spectrophotometer (Shimadzu Corporation, Kyoto, Japan), Steri-Cult 
CO2 incubator (Labotec, South Africa), Automated Chemistry Analyzer (Labmax Plenno, 
Labtest Inc., Lagoa Santa, Brazil), Glucometer (Glucoplus Inc., Saint-Laurent, Quebec, 
Canada), Ultra Turrax Tube Drive Work Station Homogenizer (IKA-Works, Staufenim 
Breisgau, Germany), Hettich Mikro 200 Microcentrifuge (Hettich Lab Technology, Tuttlingen, 
Germany), Synergy HTX Multi-mode Reader (BioTek Instruments Inc, Winooski, USA), 
Microfuge 20R Centrifuge (Beckman Coulter, Inc., Germany), Eppendorf™ 5810R Centrifuge 






2.3. In vitro Studies 
2.3.1. DPPH radical scavenging activity 
Principle: DPPH (1, 1- Diphenyl-2-picrylhydrazyl) is a stable free radical with red color 
(maximum absorbance at 517 nm). If free radicals have been scavenged, DPPH will change 
the red color to yellow.  
Procedure: The free radical scavenging activity of caffeine was determined and comparison 
was made to gallic acid, ascorbic acid and trolox according to the method described by (Ak 
and Gülçin 2008). Briefly, 80 µL of a 0.3 mM solution of 1,1-diphenyl-2-picryl-hydrazyl 
(DPPH) in distilled water was mixed with 170 µL of caffeine at different concentrations (15, 
30, 60, 120, 240 µg/mL). These solutions were incubated at dark for 30 min at room 
temperature. The absorbance of the solutions was measured at 517 nm against blank, lacking 
the free radical scavenger. 
All assays were carried out in triplicate. The DPPH radical scavenging activity was measured 
by using following formula: 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [
(𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒)
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
] 𝑥100 
2.3.2. Ferric reducing antioxidant power assay (FRAP) 
Principle: The FRAP assay uses antioxidants as reductants in a redox-linked colorimetric 
method employing an easily reduced oxidant, Fe (III). Reduction of a ferric (III) [colorless] to 
ferrous (II) [blue] can be measured photometrically. The absorbances are related to the 
reducing power of the electron-donating antioxidants present in the test sample.  
Procedure: Briefly, 300 µL of caffeine at different concentrations (15, 30, 60, 120, 240 
µg/mL), were incubated with 300 µL of sodium phosphate buffer (pH 6.6) and 1% potassium 
ferricyanide in a water bath at 50oC for 30 min. Thereafter, the solution was acidified with 300 
µL of 10% trichloroacetic acid and 300 µL of this sample was then added to 300 µL of distilled 
water and 0.1 µL of 0.1% FeCl3. The absorbance of the solution was measured at 700 nm and 
the results were expressed as gallic acid equivalent.  






% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑔𝑎𝑙𝑙𝑖𝑐 𝑎𝑐𝑖𝑑
] 𝑥100 
 
2.3.3. Nitric oxide (NO*) radical scavenging assay  
Principle: Sodium nitroprusside in aqueous solution at physiological pH spontaneously 
generates nitric oxide (NO), which interacts with oxygen to produce nitrite ions that can be 
measured by using Griess reagent. Scavengers of NO compete with oxygen, leading to reduced 
production of NO (Kurian et al., 2010).  
Procedure: The assay was carried out by incubating 500 µL of 10 mM sodium nitroprusside 
in phosphate buffer (pH 7.4) solution and 500 µL of caffeine with different concentrations (15, 
30, 60, 120, 240 µg/mL), at 37oC for 2 h. The reaction mixture was then mixed with 500 µL of 
Griess reagent.  The absorbance of the chromophore formed during the diazotization of nitrite 
with sulphanilamide and subsequent coupling with napthylethylenediamine was read at 546 
nm. Percentage inhibition of nitric oxide generated was measured by comparing the absorbance 
of control (10 mM sodium nitroprusside in phosphate buffer) with the absorbance of sample. 
All assays were carried out in triplicate. The nitric oxide radical scavenging power of the 
samples was calculated by using following formula: 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [




2.3.4. Hydroxyl radical (OH*) scavenging assay (Deoxyribose method) 
Principle: Hydroxyl radical scavenging activity of caffeine was measured by studying the 
competition between deoxyribose and caffeine for hydroxyl radical generated by ascorbate–
EDTA– H2O2 system (Fenton reaction) as described by (Hinneburg, Dorman et al. 2006).  
Procedure: The assay was performed by sequentially adding 200 µL of premixed 100 µM 
FeCl3 and 100 µM EDTA (1:1 v/v) solution, 100 µL of 10 mM H2O2, 360 µL of 10 mM 2-
deoxy-D-ribose, 1 mL caffeine with different concentrations (15, 30, 60, 120, 240 µg/mL), 400 
µL of 50 mM sodium phosphate buffer (pH 7.4) and 100 µL of 1 mM ascorbic acid in sequence. 
The mixture was then incubated at 50oC for 2 h. Thereafter, 1 mL of 2.8% TCA and 1 mL of 





incubated in a water bath at 50oC for 30 min to develop the pink chromogen. The extent of 
oxidation was estimated from the absorbance of the solution at 532 nm and the hydroxyl radical 
scavenging activity of the sample is reported as percentage inhibition of deoxyribose 
degradation. 
All assays were carried out in triplicate. The scavenging activities of caffeine hydroxyl radical 
scavenging assay was calculated by using the following formula:  
𝑆𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (%)
= [




2.3.5. Measurement of in vitro alpha amylase inhibitory activity 
Principle: Alpha amylase activity can be measured by the hydrolysis of starch in the presence 
of α-amylase enzyme. This process is quantified using iodine, which gives a blue colour with 
starch. The reduced intensity of the blue colour indicates the enzyme-induced hydrolysis of 
starch into monosaccharides. If the sample compound possesses more α-amylase inhibitory 
activity, the intensity of blue colour will be less.  
Procedure: The α-amylase inhibitory activity was determined according to the method as 
described by (Shai, Masoko et al. 2010). Briefly, 250 µL of caffeine or acarbose at various 
concentrations (15, 30, 60, 120, 240 µg/mL) was incubated with 500 µL of porcine pancreatic 
amylase (2 U/mL) in 100 mM phosphate buffer (pH 6.8) at 37°C for 20 min. Thereafter, 250 
µL of 1% starch dissolved in 100 mM phosphate buffer (pH 6.8) was added to the reaction 
mixture and incubated at 37°C for 1 hour.  Dinitrosalicylate colour reagent (1 mL) was then 
added and boiled for 10 min. The absorbance of the resultant mixture was measured at 540 nm 
and the inhibitory activity was expressed as percentage of a control without the inhibitors 
(sample compound or standard, acarbose).  
All assays were carried out in triplicate. The enzyme inhibitory activity of the sample 
compound or standard acarbose has been calculated according to the following formula: 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [








2.3.6. Measurement of in vitro alpha glucosidase inhibitory activity 
The alpha glucosidase inhibitory activity was determined according to the method described 
by (Ademiluyi and Oboh 2013) with slight modifications. Briefly, 250 µL of caffeine or 
acarbose at different concentrations (15, 30, 60, 120, 240 µg/mL) were incubated with 500 µL 
of 1.0 U/mL α-glucosidase solution in 100 mM phosphate buffer (pH 6.8) at 37°C for 15 min. 
Thereafter, 250 µL of pNPG solution (5 mM) in 100 mM phosphate buffer (pH 6.8) was added 
and the mixture was further incubated at 37oC for 20 min.  The absorbance of the released p-
nitrophenol was measured at 405 nm and the inhibitory activity was expressed as percentage 
of the control without the inhibitors.  
All assays were carried out in triplicate. The α-glucosidase inhibitory activity was calculated 
in percent (%) as per following formula: 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [




2.3.7. In vitro pancreatic lipase inhibitory assay  
The method for measuring pancreatic lipase inhibitory activity of sample compound or 
standard (Orlistat) was measured by using a slightly modified method from (Kim, Lee et al. 
2010). Briefly, an enzyme buffer was prepared by the addition of a solution of porcine 
pancreatic lipase [2.5mg mL-1 in 10 mM MOPS (morpholinepropanesulphonic acid) and 1 
mM EDTA, pH 6.8]. Thereafter 169 μL of Tris buffer (100 mM Tris–HC1 and 5 mM CaCl2, 
pH 7.0) was added to 100 μL of caffeine  (15, 30, 60, 120, 240 µg/mL) at the test concentration, 
or orlistat, after which 20 μL of the enzyme buffer was added and incubated 15 min at 37°C. 
A  5 μL of the substrate solution [10 mM p-NPB (p-nitrophenyl butyrate) in dimethyl 
formamide] was then added and incubated for 30 min at 37°C. The lipase activity was 
determined by measuring the hydrolysis of p-NPB to p-nitrophenol at 405 nm. 
The lipase inhibitory activity of caffeine on lipase were calculated by using the following 
formula: 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = [








2.4. Ex vivo studies 
Animal procedures 
Five adult male Sprague-Dawley rats were procured from the Biomedical Resource Centre 
located at the Westville Campus of the University of KwaZulu-Natal, Durban, South Africa. 
The animals were fasted over-night (12 h) and euthanized with halothane anesthesia. The 
pancreas, the entire gastrointestinal tract (GIT) and parts of the psoas muscle were harvested 
after dissection and instantly used for antioxidative stress assays, glucose absorption and 
muscle glucose uptake studies respectively. All animal procedures were carried out according 
to the rules and regulations of the Animal Ethics Research Committee of University of 
KwaZulu-Natal, South Africa (Ethical approval number: AREC/003/017D). 
2.4.1 Ex vivo antioxidative studies 
➢ Preparation of tissue homogenate 
Half a gram (0.5 g) of freshly excised pancreatic tissue was homogenized in 5 mL of 
homogenization buffer (50mM sodium phosphate buffer with 10% Triton X-100, pH 7.5). The 
homogenate was centrifuged for 15 min at 15,000 rpm in a micro centrifuge. The supernatant 
was collected and stored at −20°C for further analysis. 
➢ Induction of tissue oxidative stress and treatment 
Oxidative stress was induced in pancreatic tissue as described by Oboh et al., 2013. A 30 μL 
of 15mM ferrous phosphate (FeSO4) was incubated with 100 μL of different concentration (15, 
30, 60, 120, 240 µg/mL) of the compound and standard (gallic acid) and the pancreatic tissue 
homogenate for 30 min at 37 °C. A reaction containing no compound and ferrous phosphate 
was served positive control (normal) while reaction with no compound was served as a negative 
control (untreated).  
2.4.1.1 Determination of lipid peroxidation 
Lipid peroxidation was carried out according to the method of Oboh et al., 2013, with slight 
modifications. A 200 μL of 8.1% of SDS solution, 750 μL of 20% acetic acid, 2 mL of 0.25% 
TBA solution and 850 μL of miliQ water were added to the solution containing tissue 
homogenate and boiled for an hour. After cooling, the absorbance was measured at 532 nm. 






2.4.1.2 Determination of reduced glutathione (GSH) activity  
Determination of GSH activity was carried out according to the method described by Ellman 
et al., 1959. 100 µL of the incubated sample was added to 200 µL of 10% TCA and centrifuged 
at 3500 rpm for 5 min. Thereafter, 200 µL of the supernatant was added to a 96-well plate and 
the absorbance was measured at 415 nm. GSH concentrations of samples were calculated from 
the GSH standard curve. 
2.4.1.3 Determination of superoxide dismutase (SOD) enzyme activity 
Briefly, 170 μL of 0.1mM diethylenetriaminepentaacetic acid (DETAPAC) and 15 μL of the 
solution were placed in a 96-well plate. Then 15 μL of 1.6mM 6-hydroxydopamine (6-HD) 
was added and the mixture was quickly mixed by gently tapping all four sides of the plates. 
Absorbance was recorded at 492 nm for 3 min at 1 min interval. SOD enzyme activity was 
calculated using the following formula: 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
(𝐴1 − 𝐴𝑏)
𝜀490 × 𝑅𝑉 × 𝐷𝑓/𝑆𝑣
 
ε490 = Molar absorptivity at 490 nm = 1.742/mM/cm 
A1 and Ab = Reaction rate for sample and blank respectively 
RV = Reaction Volume; Df = Dilution factor; Sv = Sample volume 
2.4.1.4 Determination of catalase activity 
Catalase activity was determined using a spectrophotometric molybdate method as described 
by (Chance et al., 1955).  Briefly, 100 μL of the incubated tissue homogenate was mixed and 
incubated at 37 °C with 1000 μL of 65 μM H2O2 in 6.0mM sodium phosphate buffer, pH 7.4 
for 2 min. The reaction was stopped by adding 4000 μL of 32.4mM of ammonium molybdate 
and the color change in the yellowish molybdate/H2O2 complex was measured at 347 nm 
against the reagent blank that contains only H2O2. The standard tube contained all the reagents 
except the tissue sample, and the control test tube contained all other reagents except H2O2. 
Catalase activity was calculated using the following formula: 
CAT activity (kU)=2.303/t * log [So/(S-M)] * Vt/Vs 
t: time, S°: absorbance of standard tube, S: absorbance of test tube, M: absorbance of control 





2.4.2 Measurement of glucose absorption in isolated rat jejunum 
The effect of caffeine on glucose absorption in isolated rat jejunum (proximal part of small 
intestine) was determined by using method as modified from Hassan et al., (2010) and 
described in the following sections.  
➢ Preparation of reagents 
Preparation of 1 L Kreb’s buffer: Kreb’s buffer is composed of 118 mM sodium chloride 
(NaCl), 5 mM potassium chloride (KCl), 1.328 mM calcium chloride dehydrate (CaCl2.2H2O), 
1.2 mM potassium mono-basic phosphate (KH2PO4), 1.2 mM magnesium sulphate (MgSO4) 
and 25 mM sodium hydrogen bi-carbonate (NaHCO3). A 1 L of Kreb’s buffer was prepared by 
dissolving 6.896 g of NaCl (M.W., 58.44 g/mol), 0.373 g of KCl (M.W., 74.56 g/mol), 0.188 
g of CaCl2.2H2O (M.W., 147.02 g/mol), 0.163 g of KH2PO4 (M.W., 136.09 g/mol), 0.144 g of 
MgSO4 (M.W., 120.37 g/mol) and 2.10 g of NaHCO3 (M.W., 84.01 g/mol) in 1 L of autoclaved 
dH2O. 
Preparation of 500 mL of 11.1 mM glucose Kreb’s solution (GKS): This was prepared by 
dissolving 0.9999 g of D-glucose (M.W., 180.16 g/mol) in 500 mL of Kreb’s buffer. 
2.4.2.1 Assay procedure 
The assay was performed in three replicates. Five 5 cm length of jejunum was cut from isolated 
GIT of rats and each jejunum was rinsed by injecting 2 mL of Kreb’s buffer through the jejunal 
lumen using a sterile syringe. Rinsed jejuna were first inverted to expose their inner wall and 
villi, and then incubated in incubation tubes containing 8 mL each of GKS solution without 
(control) or with caffeine at different concentrations (60, 120, 240 µg/mL) for 2 h in a Steri-
Cult CO2 incubator (Lasec, South Africa) at 5% CO2, 95% oxygen and 37ºC condition. A 1 mL 
aliquot was collected from each incubation solution before and after incubation and the glucose 
concentrations were measured in milligram per deciliter (mg/dL) with Thermo Scientific 










2.4.2.2  Calculation of intestinal glucose absorption 
The absorption of intestinal glucose was calculated as the amount of glucose (mg) absorbed 
per centimeter of rat jejunum using the following formula: 
Intestinal glucose absorption = [(GC1 - GC2) / length of jejunum taken in cm] 
GC1: glucose concentrations (mg/dL) before incubation 
GC2: glucose concentrations (mg/dL) after incubation 
2.4.3 Measurement of glucose uptake in isolated rat psoas muscles 
The effect of caffeine on glucose uptake in isolated rat psoas muscles was determined 
according to method modified from Abdel-Sattar et al., (2012). 
2.4.3.1  Assay procedure 
The assay was carried out in triplicates. Three pieces of 0.5 g of psoas muscle was cut from 
each rat and incubated in incubation tubes containing 8 mL of GKS without (control) or with 
the different concentrations of caffeine solutions (60, 120, 240 µg/mL) or 1 mg/mL metformin 
solution (positive control) for 1 h in a Steri-Cult CO2 incubator (Labotec, South Africa) at 5% 
CO2, 95% Oxygen at 37ºC condition. A 1 mL aliquot was collected from each incubation tube 
before and after incubation and the glucose concentrations were measured in milligram per 
deciliter (mg/dL) by using Thermo Scientific glucose kit in a Labmax Plenno chemistry 
analyzer (Labtest Inc., Costa Brava, Brazil). 
2.4.3.2 Calculation of muscle glucose uptake 
The muscle glucose uptake was calculated as the amount of glucose absorbed per gram of rat 
psoas muscle using the following formula: 
Muscle glucose uptake = [(GC1 - GC2) / amount of muscle in gram] 
GC1: glucose concentrations (mg/dL) before incubation 








2.5 In vivo Studies 
2.5.1. Experimental animals  
Forty male Sprague-Dawley (six-week-old) rats with a mean body weight (BW) of 160-200g 
were obtained from the Biomedical Resource Unit (BRU) located at the University of 
KwaZulu-Natal (Westville Campus), South Africa. The rats were maintained as 7 in one large 
sized polycarbonated cage in a humidity (40-60%) and temperature (23 ± 1oC) controlled room 
with a 12-hour light–dark cycle.  A standard rat pellet diet was supplied ad libitum for the entire 
duration of the experiment. All animal procedures were carried out according to the rules and 
regulations of the Animal Ethics Research Committee of University of KwaZulu-Natal, South 
Africa (Ethical approval number: AREC/003/017D). 
2.5.2. Animal grouping  
The rats were randomly divided into seven groups of seven animals each namely:   
➢ Normal control (NC)  
➢ Diabetic control (DBC)  
➢ Diabetic caffeine low dose - 10 mg/kg BW (DCAFL)  
➢ Diabetic caffeine medium dose - 20 mg/kg BW (DCAFM)  
➢ Diabetic caffeine high dose - 40 mg/kg BW (DCAFH)  
➢ Diabetic metformin – 200 mg/kg BW (DM)  
 
2.5.3. Induction of diabetes   
The animals were allowed to acclimatize for one week. During the first 2 weeks of the 
experiment, the animals in the diabetic groups were supplied with 10% fructose solution ad 
libitum instead of drinking water to induce insulin resistance while the animals in the NC group 
were supplied with normal drinking water. Thereafter, animals in the diabetic groups were 
intraperitoneally injected with a low dose of streptozotocin (40 mg/kg body weight) dissolved 
in 0.1 M citrate buffer (pH 4.5) to induce partial pancreatic β-cell dysfunction, while the 
animals in NC group were injected with a similar volume of citrate buffer only. One week after 
the streptozotocin injection, the non-fasting blood glucose (NFBG) levels of all animals were 
measured in the blood collected from the tail vein by using a portable glucometer, and the 
animals with NFBG level > 200 mg/dL were considered diabetic. Animals with a NFBG level 






2.5.4. Intervention trial 
After the confirmation of diabetes, the respective dose of caffeine was orally administered five 
days in a week by using a gastric gavage needle to the rats in DCAFL, DCAFM and DCAFH 
groups while the rats in controls (NC and DBC) and DM groups were treated with a similar 
volume of the vehicle and metformin respectively for a 5-week experimental period. During 
this period, daily food and fluid intakes as well as weekly body weight changes and non-fasting 
blood glucose (NFBG) concentrations were measured in all animal groups.   
2.5.5. Oral glucose tolerance test (OGTT)  
The OGTT was conducted in the last week of the 5-week intervention period to measure the 
glucose tolerance ability of each animal. To perform this test, a single dose of glucose solution 
(2 g/kg BW) was orally ingested into each animal and the levels of blood glucose were 
measured at 0 (just before the ingestion of glucose), 30, 60, 90 and 120 min after the dose of 
glucose. 
2.5.6. Collection of blood and organs   
At the end of the 5-week experimental period, the rats were euthanized by ISOFOR anesthesia 
and the blood and organ samples were collected. Cardiac puncture method was used to collect 
the whole blood from each rat which was immediately preserved in a refrigerator until further 
processing. The blood samples were centrifuged at 3000 rpm for 15 min and serum from each 
blood sample was separated and kept at –30°C for subsequent analysis. The brain, liver, kidney 
and heart and pancreas were collected from each rat, rinsed with normal saline, wiped with 
filter paper, weighed and kept at –30°C until further analysis. A small portion of the pancreas 
sample from each rat was cut and immersed into 10% neutral buffered formalin and stored at 
room temperature for histopathological analysis.  
2.5.7 Principles for TC, TG, HDL and LDL cholesterol determination 
An automated Chemistry Analyzer and biochemical test kits were used to determine the 
concentration of total cholesterol (TC), triglycerides (TG), high density lipoproteins (HDL) 
cholesterol, low density lipoproteins (LDL) cholesterol, transaminase (AST), alkaline 








Total cholesterol (TC): 
For total cholesterol (TC) determination, cholesterol esterase hydrolyzes cholesterol esters to 
yield fatty acids and cholesterol. 
Cholesterol esters              Cholesterol Esterase                   Cholesterol + Fatty acids 
Cholesterol oxidase then oxidizes the free cholesterol to cholest-4-en-one and hydrogen 
peroxide. 
Cholesterol + O2                    Cholesterol oxidase                       Cholest-4-en-one + H2O2 
Lastly, phenol and 4-aminoantipyrine are oxized by peroxidase to yield quinoneimine which 
has a maximum absorption at wavelength 500 nm. The intensity of the pink colour, due to the 
end point reaction, is directly proportional to the concentration of cholesterol in the serum 
samples. 
2H2O2+ Phenol + 4-Aminoantipyrine               Peroxidase                   Quinoneimine + 4H2O 
Triglyceride (TG): 
For triglyceride (TG) determination, triglycerides are hydrolyzed by lipoprotein lipase to yield 
glycerol which in turn is converted to glycerol-3-phosphate by glycerolkinase and further 
oxidized to dihydroxyacetone and hydrogen peroxide by the enzyme glycerolphosphate 
oxidase. 
Triglyceride            Lipoprotein Lipase                   Glycerol + Fatty acids 
Glycerol + ATP              Glycerol kinase / Mg2+          Glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + O2        Glycerol-3-phosphate oxidase     Dihydroxyacetone + H2O2   
HDL-cholesterol: 
The HDL cholesterol test involves the selective precipitation of LDL cholesterol and very low-
density lipoproteins (VLDL) cholesterols from the serum samples using phosphotungstic acid 
and magnesium chloride. This is obtained by centrifugation and the concentration of HDL 
cholesterol in the serum samples is measured in the resulting supernatant using the total 







The concentration of LDL cholesterol in the serum samples were determined using the 
following formula below: 
LDL cholesterol = {Total cholesterol – (HDL cholesterol + VLDL cholesterol*)} 
*VLDL cholesterol = Triglycerides / 5 
 
2.5.8 Principles for fructosamine, creatinine and urea determination 
Fructosamine: 
When glucose binds to the amino groups of proteins it yields a Schiff’s base (aldimine). It 
undergoes molecular rearrangements and transforms into fructosamine which is a stable 
ketoamine (Kyle et al., 2008). In this fixed-time kinetic method test, fructosamine is converted 
to an enolic form at an alkaline pH of 10.3 and reduces nitroblue tetrazolium (NBT) to a “purple 
formazan”. The difference in absorbance values at 530 nm after incubation of samples with 
nitro blue tetrazolium for 10 and 15 minutes is proportional to the fructosamine concentration 
in the serum samples.  
Fructosamine           pH 10.3         Fructosamine (alkenol form) 
                                                                                    NBT2+ 
 
                                                                                    NBT+ 
                                                                                 
                                                                               Formazan 
                                               NBT - Fructosamine adduct 
Creatinine: 
The concentration of creatinine in serum samples was determined by a colorimetric method. 
Creatinine reacts with alkaline picrate in an alkaline solution thus yielding a red complex that 
is measured photometrically at 510 nm. When acetic acid is added the pH decreases to 5.0 and 





remains unchanged and it is also read photometrically. The differences in absorbance 
measurements yields a true value of creatinine in the sample. 
Creatinine + Alkaline picrate         Alkaline pH                    Creatinine – Picrate adduct 
 
           
      
                                                                                         Creatinine + Picric acid 
Urea: 
Urea is determined by an enzymatic two-point, fixed-time kinetic method. This test involves 
the breakdown of urea to ammonia by the enzyme urease. Ammonia is then reacted with NADH 
and 2-ketoglutarate, catalyzed by glutamate dehydrogenase, which leads to the oxidation of 
NADH to NAD and the formation of L-glutamate. The resulting reduction in absorbance is 
measured at 340 nm and it is proportional to the concentration of urea in the samples. 
Urea + H2O2             Urease                NH3 + CO2 
 
2-ketoglutarate + NH3 + NADH       Glutamate Dehydrogenase       L-glutamate + NAD 
 
2.5.9 Principles for ALP, AST determination 
Aspartate transaminase (AST): 
Aspartate transaminase (ASAT) plays a role in catalyzing the transfer of amino groups from 
aspartic acid to ketoglutarate which yields oxalacetate and glutamate. Malate dehydrogenase 
reduces oxalacetate to malate and oxidizes NADH to NAD. Oxidation of NADH causes a 
reduction in absorbance at 340 nm and it is monitored photometrically since it is directly 
proportional to the activity of ASAT in the serum samples. 






Oxalacetate + NADH                 Malate Dehydrogenase             Malate + NAD 
Alkaline phosphatase (ALP): 
For alkaline phosphatase (ALP) determination, ALP hydrolyzes p-nitrophenylphosphate to 
yield p-nitrophenol and inorganic phosphate (Pi) in an alkaline pH solution. The amount of p-
nitrophenol formed is directly proportional to the activity of ALP enzymes in the serum 
samples. 
p-Nitrophenylphosphate + H2O       Alkaline phosphatase        p-Nitrophenol + inorganic 
phosphate 
 
2.5.10 Serum insulin determination and calculation of HOMA-β and HOMA-IR scores 
The concentrations of serum insulin were measured by an enzyme-linked immunosorbent assay 
(ELISA) method using an ultrasensitive rat insulin ELISA kit in a multi-plate ELISA reader. 
The serum lipid profile (total cholesterol, HDL- and LDL cholesterols, and triglycerides), 
fructosamine, urea and creatinine concentrations as well as liver function enzymes were 
measured with an Automated Chemistry Analyzer. Computation of the homeostatic model 
assessment (HOMA-IR and HOMA-β) using were conducted using serum insulin and FBG 
concentrations measured at the end of the experimental period using the formula below: 
HOMA-IR = [Insulin (U/l) × Blood glucose (mmol/L)] / 22.5 
HOMA-β = [20 × Insulin (U/l)] / [Blood glucose (mmol/L) – 3.5] 
Conversion factor: Insulin (1 U/l = 7.174 pmol/L) 










2.5.11 Liver glycogen determination  
2.5.11.1 Preparation of reagents and standards  
➢ 30% KOH saturated with Na2SO4 solution: A 30 g of KOH (M.W. of 56.11 g/mol) was 
dissolved in 100 ml of distilled water and Na2SO4 (M.W. of 142.04 g/mol) was added 
until it was unable to be saturated.  
➢ 5% phenol solution: A 5 g of phenol (M.W. of 94.11 g/mol) was dissolved in 100 ml 
distilled water.  
➢ Glycogen stock solution: A 5 mg of glycogen was dissolved in 5 ml distilled water (1 
mg/ml).  
➢ Glycogen standards: 5, 10, 20, 40, 80, 160, 320, and 640 μL of the glycogen stock 
solution were each diluted in 995, 990, 980, 960, 920, 840, 680, and 360 μL of distilled 




The liver glycogen levels were measured photometrically using the phenol-sulphuric acid 
method as described by Lo et al., (1970). Liver samples (< 1.0 g) were weighed, placed in the 
bottom of Eppendorf tubes with forceps and then placed on ice. The samples were immersed 
with 1.5 ml of 30% potassium hydroxide (KOH) saturated with sodium sulphate (Na2SO4) and 
placed in a boiling water bath for 30 minutes or more for digestion of liver tissue. The samples 
were then removed from the water bath and cooled on ice. Once cooled, 2 ml of 95% ethanol 
was added and placed on ice for a further 30 minutes. The digested liver samples were then 
centrifuged at 840 x g (2812 rpm) for 30 minutes. The resulting supernatant was aspirated, and 
the glycogen precipitate was dissolved in 3.0 mL of distilled water. A 100 μL of this solution 
was transferred into a clean test tube containing 900 μL of distilled water. Glycogen standards 
at concentrations of 5, 10, 20, 40, 80, 160, 320 and 640 μg/mL were prepared from a stock 
solution of 1 mg/mL glycogen (Oyster, Type II, Sigma-Aldrich, USA). The samples and 
standards were prepared in duplicates. Once the samples and standards were prepared, 1 ml of 
5% phenol was added followed by the rapid addition of 5 ml 96-98% sulphuric acid (H2SO4). 
The samples and standards were left to stand for 10 minutes at room temperature and the 
absorbance was then read at 490 nm using a spectrophotometer. Distilled water was used as a 







2.5.12 Assay of specific antioxidant enzymes and lipid peroxidation  
 
➢ Preparation of homogenization buffer:  
A 50 mM sodium phosphate buffer with triton X-100 at pH 7.4 was prepared as follows:   
2.998 g of monobasic sodium phosphate (M.w., 119.98 g/moL) was dissolved in distilled water 
(dH2O) and the volume brought up to 500 mL in a volumetric flask to yield a 500 mL of a 50 
mM mono-basic sodium phosphate solution. A 3.525 g of dibasic sodium phosphate (M.w., 
141.56 g/mol) was dissolved in dH2O and the final volume made up to 500 mL in a volumetric 
flask to yield a 500 mL of 50 mM dibasic sodium phosphate solution. While stirring, the 
prepared 50 mM mono-basic sodium solution was added, steadily, to the prepared 50 mM 
dibasic sodium phosphate solution, until a pH of 7.4 was attained. A 0.5 % (v/v) triton X-100 
was added to the above mixture and the pH was again adjusted to 7.4 with 50 mM mono-basic 
sodium phosphate solution. The buffer was then stored at 4℃ until further use. 
➢ Preparation of sample homogenates  
0.5 g of each organ was weighed and finely minced for better homogenization. The finely 
minced tissues were homogenized with an electronic homogenizer in 5 mL ice cold 
homogenization buffer (pH 7.4). The mixture was then transferred into 2 mL microcentrifuge 
tubes and centrifuged for 15 min at 15000 rpm using a refrigerated microcentrifuge set at 4℃. 
2.5.12.1 Determination of thiobarbituric acid reactive substance (TBARS) concentration 
as malondialdehyde (MDA) equivalent to measure level of lipid peroxidation 
This assay was aimed at determining the level of lipid peroxidation reducing activity of caffeine 
at different concentrations. It is based on the reaction between a thiobarbituric acid reactive 
substance (TBARS) such as malondialdehyde (MDA) and thiobarbituric acid. When incubated 
at 95℃, a red, fluorescent 1:2, MDA: TBA adduct forms which can be spectrophotometrically 
measured at an absorbance of 532 nm (Mayne, 2003).  
Preparation of reagents   
➢ 25 mL of 8.1% sodium dodecyl sulfate (SDS) solution  
2.025 g of SDS (M.w., 288.38 g/mol) was dissolved in MiliQ water and the final volume was 






➢ 100 mL of 20% acetic acid solution (pH 3.5)   
20 mL of glacial acetic acid was made up to 100 mL with MiliQ water and a sodium hydroxide 
solution was used to adjust the pH of the solution to 3.5.   
➢ 250 mL of 0.25% TBA solution  
0.625 g of TBA (M.w., 144.14 g/mol) was dissolved in MiliQ water and the final volume was 
made up to 250 mL with MiliQ water in a volumetric flask.  
Procedure 
Thiobarbituric acid reactive substances, expressed as MDA concentration were measured to 
determine the extent of lipid peroxidation using the protocol described by Fraga et al., (1957). 
A 200 µL of the sample or MDA standards were thoroughly mixed with 200 µL of 8.1% SDS 
solution, 750 µL of 20% acetic acid, 2 mL of 0.25% TBA and 850 µL of distilled water. 
Subsequently, the resulting mixture was heated in a water bath at 95ºC for 1 hour and allowed 
to cool to room temperature. The absorbance of the resulting solution was then read at 532 nm 
and the concentration of TBARS in the samples was calculated from the MDA standard curve.  
Calculation of MDA concentrations of samples  
A standard curve was obtained by plotting the absorbance read at 532 nm of the MDA standards 
against their corresponding concentrations using Microsoft Excel, 2016. From this standard 
curve, the MDA concentration of each sample was extrapolated from their respective 
absorbance at 532 nm.   
2.5.12.2 Determination of reduced glutathione (GSH) level  
The principle of this assay involves the oxidation of GSH by 5, 5’-dithio-bis (2-nitrobenzoic 
acid) (DTNB) to 5’-thio-2-nitrobenzoic acid (TNB), which is a yellow derivative that is 
measurable at 415 nm. The formed GSSG can be recycled to GSH by glutathione reductase in 
the presence of NADPH (Rahman et al., 2006). 
Preparation of reagents  
➢ 50 mL of 0.2 M sodium phosphate buffer (pH 7.8)  
A 50 mL of 0.2 M mono-basic sodium phosphate solution was prepared by dissolving a 1.199 
g of mono-basic sodium phosphate (M.w., 119.9 g/mol) in distilled water and the final volume 
was made up to 50 mL with distilled water. A 100 mL of 0.2 M dibasic sodium phosphate 





g/mol) in distilled water and the final volume was made up to 100 mL with distilled water. 0.2 
M mono-basic sodium phosphate solution was steadily added to the 0.2 M dibasic sodium 
phosphate solution, while stirring until a pH of 7.8 was reached. This was then stored at 4 ℃ 
until further use.   
➢ 20 mL of 10% TCA solution  
2 g of TCA (M.w., 163.4 g/mol) was dissolved in MiliQ water and the final volume was brought 
up to 20 mL with MiliQ water.   
➢ 50 mL of 0.5 mM DTNB solution  
0.01 g of DTNB (M.w., 396.35 g/mol) was dissolved in MiliQ water and the final volume was 
brought up to 50 mL with MiliQ water in a volumetric flask.    
Assay procedure  
Reduced glutathione concentration was measured in tissue samples. All samples were first 
precipitated with 10% TCA (300 µL TCA was added to 300 µL of each sample) and then 
centrifuged at 2000 rpm for 10 min at room temperature (25 ℃). 
Into a 96-well plate, the following reaction mixture, containing 80 µL of supernatant, 40 µL of 
0.5 mM DTNB and 200 µL of 0.2 M sodium phosphate buffer (pH 7.8), was added. The 
absorbance of this reaction mixture was then measured at 415 nm after 15 min incubation at 
25℃.    
Calculation of GSH concentration of samples  
A standard curve was obtained by plotting the absorbance read at 415 nm of the GSH standards 
against their related concentrations using Microsoft Excel, 2016. From this standard curve, the 
GSH concentration of each sample was extrapolated from their respective absorbance at 415 










2.5.12.3 Determination of catalase (CAT) activity 
Principle 
Catalase activity was determined according to the method of Sinha A., 1971. This method is 
based on the fact that dichromate in acetic acid is reduced to chromic acetate when heated in 
the presence of H2O2, with the formation of perchromic acid as an unstable intermediate. The 
chromic acetate then produced is measured colorimetrically at 570-610nm. Since dichromate 
has no absorbency in this region, the presence of the compound in the assay mixture does not 
interfere at all with the colorimetric determination of chromic acetate. The catalase preparation 
is allowed to split H2O2 for different periods of time. The reaction is stopped at a particular 
time by the addition of dichromate/acetic acid mixture and the remaining H2O2 is determined 
by measuring chromic acetate colorimetrically after heating the reaction mixture.  
Preparation of reagents 
➢ 5% K2Cr2O7 (Dichromate Solution)  
5g of K2Cr2O7 (Hopkins & Williams, England) was dissolved in 80mL of distilled water and 
made up to 100mL with same.  
➢ 0.2M H2O2 (Hydrogen peroxide) 
11.50 mL of 30% (w/w) H2O2 was diluted with distilled water in a volumetric flask and the 
solution made up to 500 mL. 
➢ Dichromate/acetic acid 
This reagent was prepared by mixing 5% solution of K2Cr2O7 with glacial acetic acid (1:3 by 
volume) and could be used indefinitely.    
➢ Phosphate buffer (0.01M, pH 7.0) 
3.58g of Na2HPO4 12H2O and 1.19g NaH2PO4 2H2O dissolved in 900mL of distilled water. 
The pH adjusted to 7.0 and distilled water added to make up to 1 litre.  
Assay procedure 
Colorimetric determination of H2O2: Different amounts of H2O2, ranging from 10 to 100 
moles were taken in small test tubes and 2mL of dichromate/acetic acid was added to each. 
Addition of the reagent instantaneously produced an unstable blue precipitate of perchromic 
acid. Subsequent heating for 10 minutes in a boiling water bath changed the colour of the 





the volume of the reaction mixture was made to 3ml and the optical density measured with a 
spectrophotometer at 570nm. The concentrations of the standard were plotted against 
absorbance. 
Calculation of catalase activity of samples 
Catalase activity was calculated by plotting the standard curve and the concentration of the 
remaining H2O2 was extrapolated from the curve.  
H2O2 consumed = 800µmoles – H2O2 remaining 
Catalase activity = H2O2 consumed /mg protein  
 
2.5.13 Histopathological examination of pancreatic tissues 
Immediately after the collection of the pancreas, a small section was cut and placed in a 1 mL 
eppendorf tube containing 10% neutral buffered formalin solution. Formalin was changed 
weekly until all tissues were processed. For tissue processing, the section of each organ 
collected was dehydrated in 2 changes of 70% Ethanol (EtOH) of 1 hour each, followed by 1 
change of 80% EtOH for 1 hr, 1 change of 90% EtOH for 1 hr and 1 change of 100% EtOH 
overnight. After which the tissues were cleared in 3 changes of xylene for 1.5 hrs each. Tissue 
sections were then embedded in paraffin wax. The paraffin blocks were trimmed to the 
appropriate size. Sections were cut at 3 μm and placed in a 40-45˚C water bath. Thereafter, 
sections were mounted onto slides and allowed to air-dry overnight. Following air drying, the 
slides were deparaffinised in 2 changes of xylene for 5 and 2 min respectively. Slides were then 
rehydrated in 1 change of 100% EtOH for 2 min, 1 change of 90% EtOH for 2 min, 1 change 
of 70% EtOH for 2 min, 1 change of 50% EtOH for 2 min, and then placed in d.H2O. Slides 
were stained with haematoxylin as the primary stain for 5 min and washed under running water. 
Slides were then counterstained with eosin for 3 min. The slides were dipped in 90-100% EtOH 
followed by xylene, wiped and cover slipped using DPX mounting agent cover-slipped and 
viewed with Leica slide scanner (SCN 4000, Leica Bio-systems, Germany). 
2.6 Statistical analysis 
All data are presented as mean ± SD. Data were analysed using a statistical software package 
(SPSS for windows, USA), by using one-way ANOVA and Tukey’s HSD post hoc test. 











































3.1 In vitro Studies 
3.1.1 DPPH- 1,1-diphenyl-2-picrylhydrazyl Radical Scavenging Activity 
The DPPH radical scavenging activities of caffeine are presented in Figure 3.1. Caffeine 
demonstrated powerful free radical scavenging activity which were similar with most other 
standard antioxidants used in this experiment. 
 
Figure 3.1: DPPH radical scavenging activity of caffeine and standard drugs. Data are 
presented as mean ± SD. abValues with different letters over the bars for a given concentration 



































3.1.2 Ferric reducing antioxidant power (FRAP) assay 
The total reducing power (in terms of percentage gallic acid equivalent) of caffeine was 
compared to ascorbic acid and presented in Figure 3.2. According to the results, the total 
reducing power of caffeine was found to increase steadily with increasing concentrations of the 
samples. However, caffeine demonstrated significantly (p<0.05) lower Fe3+ to Fe2+ reductive 
ability than the standard compound used (Ascorbic acid) in this experiment. 
 
Figure 3.2: Ferric reducing antioxidant power of the different concentrations of caffeine and 
ascorbic acid (Standard). Data are presented as mean ± SD. abValues with different letters over 
the bars for a given concentration are significantly different from each other (Tukey’s-HSD 
























































3.1.3 Nitric Oxide (NO) Scavenging Activity 
Although a similar NO scavenging effects was observed for caffeine with other standard 
compounds at lower concentrations (15 and 30 μg/mL), standard compounds has a higher NO 
scavenging activity compared to caffeine for higher concentrations (Figure 3.3). Hence, 
caffeine may not have strong nitric oxide scavenging effects as found for ascorbic acid and 
Trolox, particularly in higher concentration (Figure 3.3).  
 
Figure 3.3: Nitric oxide (NO) scavenging activity of caffeine and standard compounds. Data 
are presented as mean ± SD. abcValues with different letters over the bars for a given 
concentration are significantly different from each other (Tukey’s-HSD multiple range post hoc 





































3.1.4 Hydroxyl radical scavenging activity (Deoxy-2- ribose assay) 
The results of the hydroxyl radical scavenging (HRS) assay showed that caffeine could 
scavenge hydroxyl radicals produced by Fenton’s reaction in a non-dose dependent manner 
(Figure 3.4). Although highest HRS activity was observed for quercetin at 240 µg/mL 
concentration and dose-dependent effects were observed for gallic acid, no such effects were 
observed for caffeine. The HRS activities of caffeine and gallic acid were relatively lower 
(<30%) even at higher concentration (240 µg/mL) used in this study.  
 
Figure 3.4: Deoxy-2- ribose hydroxyl radical scavenging (HRS) activity of caffeine. Data are 
presented as mean ± SD. abcValues with different letters over the bars for a given concentration 









































3.1.5 Measurement of in vitro inhibition of alpha amylase activity 
The alpha amylase and alpha glucosidase inhibitory activities of the caffeine and standard drug 
are shown in Figure 3.5. and 3.6. Although caffeine inhibited alpha amylase and alpha 
glucosidase activities in a non-dose dependent manner, the results were not significantly 
different among the concentrations. However, it demonstrated significantly lower (p < 0.05) α-
amylase α-glucosidase inhibitory activities compared to acarbose in all concentrations used in 
this experiment. 
 
Figure 3.5: The effect of caffeine on the activities of alpha amylase enzyme in vitro. Data are 
presented as mean ± SD. abValues with diffeerent letters over the bars for a given concentration 




































3.1.6 Measurement of in vitro inhibition of alpha glucosidase activity 
 
Figure 3.6: Effects of caffeine on alpha glucosidase enzyme activity in vitro. Data are 
presented as mean ± SD. abValues with different letter over the bars for a given concentration 









































3.1.7 In vitro pancreatic lipase inhibitory activity assay 
Although caffeine demonstrated dose-dependent anti-lipase activity, the level of inhibitory 
activities was very low at different concentrations used. The pancreatic lipase inhibitory 
activity of caffeine was also significantly lower than the standard drug (orlistat) used in this 
assay. 
 
Figure 3.7: Effect of caffeine on the activity of lipase enzyme in vitro. Data are presented as 
mean ± SD. abValues with different letters over the bars for a given concentration are 






































3.2 Ex vivo Studies  
3.2.1 The effect of caffeine on lipid peroxidation in pancreas 
The effects of caffeine on pancreatic lipid peroxidation was measured as MDA. Pancreatic 
MDA levels were significantly (p < 0.05) increased after the incubation pancreatic tissue with 
FeSO4, representing the induction of lipid peroxidation. Incubation with caffeine led to a dose–
dependent reduction of lipid peroxidation, demonstrating its anti-peroxidative effect (p < 0.05). 
 
Figure 3.8: The effect of caffeine on lipid peroxidation in pancreas. Data are presented as mean 
± SD. *Significantly different from untreated control and #Significantly different from normal 
(Tukey’s-HSD multiple range post hoc test, p<0.05). Normal = tissues not incubated with 













































3.2.2 The effect of caffeine on GSH activity in oxidative pancreatic injury. 
The GSH level was significantly (p < 0.05) depleted after the incubation of pancreatic tissue 
with FeSO4 indicating the induction of oxidative stress. However, the GSH activity was not 
significantly improved either with caffeine or standard compound (gallic acid) used in this 
study at different concentrations.  
 
 
Figure 3.9: The effect of caffeine on GSH level in oxidative pancreatic injury. Data are 
presented as mean ± SD. *Significantly different from untreated control, #Significantly 
different from normal and a,bDifferent alphabets over the bars for a given concentration are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05). 
Normal = tissues not incubated with FeSO4 or compound; Untreated = tissues incubated with 










































3.2.3 The effect of caffeine on SOD activity in oxidative pancreatic injury 
Incubation of pancreatic tissue with FeSO4 led to the reduction of SOD activity as depicted in 
Figure 3.10, further confirming the induction oxidative imbalance. These were significantly (p 
< 0.05) reversed with increasing concentration of caffeine, indicating an antioxidative activity 
of caffeine.  
 
 
Figure 3.10: The effect of caffeine on SOD activity in oxidative pancreatic injury. Data are 
presented as mean ± SD. *Significantly different from untreated control, #Significantly 
different from normal and a,bDifferent alphabets over the bars for a given concentration are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, p<0.05). 
Normal = tissues not incubated with FeSO4 or compound; Untreated = tissues incubated with 



















































3.2.4. Effects of caffeine on catalase activity in oxidative pancreatic injury. 
Incubation pancreatic tissue with FeSO4 led to decrease in catalase activity as depicted by an 
increase in H2O2 levels. These were significantly (p < 0.05) reversed with increasing 
concentration of caffeine, indicating its antioxidative activity in a non-dose dependent manner.  
 
 
Figure 3.11: The effect of caffeine on catalase activity in oxidative pancreatic injury. 
*Significantly different from untreated control, #Significantly different from normal, and 
a,bDifferent letters above the bars for a given concentrations are significantly different from 
each other (Tukey’s-HSD multiple range post hoc test, P<0.05). Normal = tissues not incubated 
with FeSO4 or compound; Untreated = tissues incubated with FeSO4 only. Data are presented 














































3.2.5. The effects of caffeine on glucose absorption in isolated rat jejunum 
The result showed that the amount of glucose absorbed by isolated rat jejunum in the presence 
of caffeine was reduced significantly in all concentrations of caffeine used in this experiment 
(Figure 3.12). These results show that caffeine has significant effects on inhibiting small 
intestinal glucose absorption. 
 
Figure 3.12: The effects of caffeine on glucose absorption in isolated rat jejunum. Data are 
presented as mean ± SD. abcValues with different letters over the bars are significantly different 

















































3.2.6. The effects of caffeine on glucose uptake in rat psoas muscle 
The data shows that the amount of glucose uptake by psoas muscle in the presence of caffeine 
increased significantly only at concentration 240 µg/mL compared to the control and other 
lower concentrations (60 and 120 µg/mL) used in this experiment (Figure 3.13). This means 
that caffeine has muscle glucose uptake enhancing activity only at higher concentrations.  
 
 
Figure 3.13: The effects of caffeine on glucose uptake in rat psoas muscle. Data are presented 
as mean ± SD. abcValues with different letters over the bars for are significantly different from 

















































Table 3.1: IC50 values of biological activities of caffeine and standard drugs 




Trolox Quercetin Acarbose Orlistat     
 (µg/mL) 
DPPH 7×10-3 5×10-7 0.163 - - - - 
FRAP >1000 28.76 - - - - - 
NO >1000 185.3 - 52.21 - - - 
HRS 1.49×1012 - >1000 - 185.67 - - 
α-amylase >1000 - - - - 9.68 - 
α-glucosidase >1000 - - - - 0.5 - 
Pancreatic lipase 2.18×1013 - - - - - 4.89×10-12 
Data are presented as mean; n =3; Lower IC50 value = better activity  
DPPH-1,1-diphenyl-2-picrylhydrazyl radical, FRAP- Ferric reducing antioxidant power, NO-
nitric oxide radical, HRS- Hydroxyl radical scavenging activity.  
 
Table 3.2: IC50 values of biological activities of caffeine and standard drugs 
Biological Activities Caffeine (µg/mL) Gallic acid (µg/mL) 
Catalase 347.84 4.28 
GSH - - 
SOD 64.14 39.45 
Lipid peroxidation 678.21 833.61 
Glucose absorption 0.0000029 - 
Glucose uptake 398.13 - 











3.3. In vivo Studies  
3.3.1. Food and fluid intake  
Figure 3.14, shows the mean food (g/rat/day) and fluid (mL/rat/day) intake in different animal 
groups over the 7-week experimental period. Food and fluid intake of diabetic experimental 
groups were significantly higher (p < 0.05) compared to the NC group when DBC group 
showed significantly lower fluid intake compared to most other treated with caffeine (except 
DCAFM) or standard anti-diabetic drugs (Figure 3.14). 
 
 
Figure 3.14: The effects of oral treatment of caffeine on food and fluid intake in the different 
group of rats. The results are expressed as mean ± SD of 7 rats. abcDifferent alphabets over the 
bars for a given parameter indicate significance of difference (Tukey’s-HSD multiple range 
















































3.3.2. Body weight (BW) change 
Figure 3.15 shows the weekly BW change over the 7-week experimental period. All the animal 
groups had a similar mean initial BW at the beginning of the study however as soon as STZ 
was injected, the BW of all diabetic groups were significantly lower (p < 0.05) compared to 
the NC group throughout the experimental period. However, although there were no significant 
differences in BW observed between the DBC and the treated groups during the early weeks, 
the BW of animals treated with the high dose of caffeine (DCAFH) and metformin (DM) was 
significantly higher than the other diabetic groups (DBC, DCAFL, DCAFM) when the 
induction of BW for DM group was significantly higher than the DCAFH group (Figure 3.15). 
 
Figure 3.15: The effects of oral treatment of caffeine on the mean body weight change in the 
different group of rats during the experimental period. The results are expressed as mean ± SD 
of seven rats. abDifferent alphabets near the lines for a given week indicate significance of 












































3.3.3. Weekly blood glucose  
Figure 3.16 shows the level of weekly blood glucose (BG) of different animal groups during 
the 5-week experimental period. The BG of the DBC and treatment groups were significantly 
higher (p < 0.05) compared to the NC group, however, the BG levels of DCAFH and DM was 
significantly lower (p < 0.05) compared to the other diabetic groups (DBC, DCAFL and 
DCAFM) (Fig. 3.16). Blood glucose was gradually decreased with the period of treatment with 
the high dose of caffeine (DCAFH) which was comparable to the effect of standard diabetic 
drug (DM). 
 
Figure 3.16: The effects of caffeine treatment on weekly blood glucose concentrations in 
different group of rats. The results are expressed as mean ± SD seven rats. a-dDifferent alphabets 
near the lines for a given week indicate significance of difference (Tukey’s-HSD multiple range 


















































3.3.4. Oral glucose tolerance test (OGTT) 
The data for OGTT are presented in Figure 3.17. The BG levels of the DCAFH group after 30 
and 120 min and the BG of DM group after 90 and 120 min were significantly lower (p < 0.05) 
than the DBC group. No significant differences were observed between the other groups at 
different time points. 
 
Figure 3.17: Oral glucose tolerance test (OGTT) for all groups of animals in the last week of 
experimental period. The results are expressed as mean ± SD of 7 rats. a-dDifferent alphabets 
near the lines for a given time indicate the significance of difference (Tukey’s-HSD multiple 
range post hoc test, p<0.05).  
 
Table 3.3: Area under the curve (AUC) values for the OGTT activity 
Area under 
curve (AUC) 
NC DBC DCAFL DCAFM DCAFH DM 
478.58 1928.71 1963.73 2140.63 1618.75 1736.67 
AUC = [(B2 + B1) / 2] × (A2 – A1)  
B1 and B2 = Initial and final blood glucose values (mg/dl) at a given time respectively  





















































3.3.5. Serum lipid profile 
Figure 3.18 shows the data for the serum lipid profile in different experimental groups. There 
was no significant difference in the level of serum triglycerides and LDL-cholesterol between 
the groups. However, the total cholesterol of DCAFL and DCAFH groups were significantly 
lower than the DC group. Additionally, HDL-cholesterol of DCAFH group was significantly 
higher than the DC, DACFL and DCAFM groups when no significant difference was observed 
among the other groups.   
 
Figure 3.18: Serum lipid profile in different animal groups at the end of the experimental 
period. The results are expressed as mean ± SD of 5-7 rats. HDL: high density lipoproteins; 












































3.3.6. Liver weights and liver glycogen 
The data for liver weight, relative liver weight and liver glycogen levels are presented in Table 
3.4. The NC, DCAFH and DM group had a significantly higher liver weight compared to all 
other groups, while relative liver weight of DCAFH group was significantly higher than the 
DBC group. Similarly, the liver glycogen DCAFH group was also significantly higher than the 
DBC group (Table 3.4). Overall the level of liver weight, relative liver weight and liver 
glycogen levels of DCAFH group were significantly higher than the DBC group when the 
results for DCAFH group were comparable to NC group. 
  


















5.69±0.99c 2.27±0.20ab 3.33±0.47ab 3.30±0.35a 4.87±0.60c 4.57±0.95ab 
The results are expressed as mean ± SD of 5-7 rats. a-cDifferent alphabets within a row are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, P<0.05) 













3.3.7. Serum insulin, fructosamine, HOMA-IR and HOMA-β 
The level of serum insulin and pancreatic HOMA-β scores or pancreatic β-cell functions were significantly higher in the DCAFH group compared 
to the DBC group when the level of serum fructosamine and HOMA-IR scores were significantly lower in the DCAFH group compared to the 
DBC group (Table 3.5). 
 




NC DBC DCAFL DCAFM DCAFH DM 
Insulin (pmol/L) 70.78±12.46c 9.53±3.20a 14.79±3.20a 18.11±6.48ab 21.53±1.71ab 44.57±0.72b 
Fructosamine(μmol/L) 569.71±69.89a 676.2±34.09c 683.20±25.71c 679±33.13c 637.67±47.80ab 645.67±32.68ab 
HOMA-IR1 1.17±0.18a 3.90±0.16d 2.21±0.5b 2.93±0.2c 2.29±0.8b 2.23±0.12b 
HOMA-β2 123.54±1.05d 1.63±0.09a 1.99±0.14a 2.23±0.27a 4.37±0.22b 11.69±0.53c 
The results are expressed as mean ± SD of 5-7 rats. a-dDifferent alphabets within a row for a given parameter are significantly different from each 
other (Tukey’s-HSD multiple range post hoc test, P<0.05). 
1HOMA-IR = [Insulin (U/l) × Blood glucose (mmol/l)] / 22.5; 2HOMA-β = [20 × Insulin (U/l)] / [Blood glucose (mmol/l) – 3.5]. HOMA: 





3.3.8. Serum creatinine, Urea, AST and ALP 
The data for serum creatinine, urea, AST and ALP are presented in Table 3.6. There was no significant difference in serum creatinine and AST 
levels, however, the ALP levels for the DCAFH and DM groups were significantly lower compared to all other diabetic groups which were also 
comparable to NC group. Results show that the serum urea levels of all diabetic groups were significantly higher than the NC group except DCAFH 
group. 
 
Table 3.6: Serum creatinine, urea, AST and ALP levels in different animal groups at the end of the 7-week experimental period. 
Serum 
parameters 
NC DBC DCAFL DCAFM DCAFH DM 
Creatinine 
(µg/dL) 
3.03±0.17 2.17±0.82 2.40±0.79 2.61±0.57 2.86±0.23 4.19±3.45 
Urea 
(mg/dL) 
41.67±6.92a 66.57±3.49b  46.33±8.59a 52.57±11.46ab 
 
43.71±8.76a  51.43±6.16a 
AST (U/L) 86.6±9.32 69.5±10.98 73.3±19.34 64.66±14.70 81.67±19.22 92.5±19.97 
ALP (U/L) 104.29±16.82a 655±128.26d 303.4±68.80c 269.60±91.92c 141.75±24.88ab 186.2±65.96ab 
The results are expressed as mean ± SD of 5-7 rats. a-bDifferent alphabets within a row are significantly different from each other (Tukey’s-HSD 





3.3.9. Thiobarbituric acid reactive substances (TBARS) assay 
The data for the concentration of TBARS as the equivalent of MDA in the various tissues and 
serum samples of different animal groups are presented in Figure 3.19. Results show that there 
was a significant decrease in the MDA concentration (p<0.05) in the DCAFH group in the brain, 
kidney, pancreas and serum compared to the DC group and the results were even lower than DM 




Figure 3.19: Malondialdehyde concentration in the serum and various organs of different animal 
groups at the end of the experimental period. The results are expressed as mean ± SD of 5-7 rats. 
a-dDifferent alphabets above the bars for a given sample are significantly different from each other 




























































3.3.10. Reduced glutathione (GSH) activity 
Figure 3.20 highlights the results obtained for the GSH assay. The induction of diabetes (DC 
group) significantly decreased the GSH concentrations in the liver, pancreas and serum as 
compared to NC group. On the other hand, treatment with high dose of caffeine (DCAFH) 
significantly (p<0.05) increased the GSH levels in the brain, liver, pancreas and serum samples 
compared to the DC group (Fig. 3.20). 
 
 
Figure 3.20: GSH concentration in different animal groups at the end of the experimental period. 
The results are expressed as mean ± SD of 5-7 rats. a-dDifferent alphabets over the bars for a given 
sample are significantly different from each other (Tukey’s-HSD multiple range post hoc test, 
















































3.3.11. Catalase Activity  
Figure 3.21 depicts the data obtained for the catalase assay. The NC, DCAFM, DCAFH and DM 




Figure 3.21: Catalase activity in different animal groups at the end of the experimental period. 
The results are expressed as mean ± SD of 5-7 rats. a-dDifferent alphabets above the bars for a 














































NC DC DCAFL DCAFM DCAFH DM
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b b b b 





























Figure 3.22: Histopathological examinations (40x) of the pancreatic islets of different animal 














The slides for histopathological examination of the pancreatic tissues are presented in Figure 
3.22. The induction of diabetes significantly damaged the pancreatic islets which was confirmed 
by the islets morphology of DBC group compared to the NC group. Although the treatment 
with the low (DCAFL) and medium (DCAFM) doses of caffeine could not recover the 
pancreatic beta-cell damage, a substantial recovery of pancreatic islets was observed in the 



















































Caffeine has been used for many years and is one of the most extensively consumed active food 
ingredient throughout the world (Andrews et al., 2007). Caffeine has been broadly studied in a 
variety of areas regarding human health and performance (Smit and Rogers 2002). Research 
suggests that caffeine can aid in reducing symptoms associated with Parkinson’s disease such 
as the deterioration of gross and small motor skills, and tremors (Trevitt et al., 2009). 
Additionally, reports have shown that consumption of coffee or caffeine containing drinks are 
associated with the reduction of T2D related symptoms, promotes weight loss and acts as an 
antioxidant. (Bhupathiraju et al., 2013; Whitehead and White, 2013). However, the 
fundamental mechanisms have not been identified. Elucidation of the causal mechanisms are 
needed before these findings can be put to therapeutic use. Therefore, the main objective of this 
study was to investigate the mechanisms behind the anti-diabetic effects of caffeine. 
A common strategy for T2D management is through the usage of potent anti-oxidative agents. 
This method affords a therapeutic option for the amelioration of chronic vascular complications 
related to oxidative stress. Preliminary anti-oxidative tests were done to determine the 
antioxidant potential of caffeine at different doses using various models.  
The model of scavenging the stable DPPH radical is a widely used to evaluate the antioxidant 
activity of pure compounds. DPPH is a free radical that can accept an electron or hydrogen 
radical to become a stable diamagnetic molecule. Hence, DPPH is usually used as a substrate 
to evaluate the free radical scavenging activity of antioxidative agents in vitro.  Using this 
model, caffeine demonstrated remarkable anti-radical activities (Figure 3.1) and a very low 
IC50 value (Table 3.1). This suggests that this compound contains powerful free radical 
scavenging activities that could have the ability to ameliorate T2D-associated complications 
and indeed other oxidative stress associated metabolic disorders. 
Antioxidants can be reductants that can inactivate oxidants and the reaction can be described as 
a redox reaction in which one reaction species is reduced at the expense of the oxidation of the 
other. Thus, the presence of antioxidant substances in the samples causes the conversion of the 
Fe3+/ferricyanide complex to the Fe2+ form which can be measured at 700 nm (Chung et al., 
2002). The reducing power of caffeine increased with increasing concentration, this suggests 
that the electron donating ability of the compound is concentration dependent. The higher 
reducing power of caffeine at the highest concentration used (Figure 3.2), suggest that the 





donors (Kahkonen et al., 1999). This is not surprising, since a recent study highlighted the 
antioxidant potential of moderate coffee consumption by human subjects (Belete and Bikila, 
2015). Nitric oxide radicals are very unstable species that has been implicated in the pathology 
of cancer, T2D and numerous other ailments (Fukumura et al., 2006). In this study, caffeine 
was able to inhibit the NO radical however in a non-dose dependant manner (Figure 3.3).  
The hydroxyl radical is a highly potent free radical in living organisms and has been implicated 
as a highly damaging species in free radical pathology that can damage all life essential 
biomolecules (Kalaivani et al., 2004). The hydroxyl radical scavenging activity is thus 
measured as the percentage of inhibition of these radicals generated in the Fenton’s reaction 
mixture (Fe3+/EDTA/ascorbate/H2O2) by studying the competition between deoxyribose and 
caffeine (Hinnerburg et al., 2006). Caffeine was found to be effective in hydroxyl radical 
inhibition (Figure 3.4). The pancreas has the lower antioxidant defence mechanisms compared 
to other organs when it is very vulnerable to hydroxyl radical (Quilliot et al., 2005). The 
hydroxyl radical scavenging activity of caffeine also proves it pancreatic beta-cell protecting 
activity. 
A commonly used and potent strategy for T2D management is the inhibition of α-glucosidase 
and α-amylase enzymes. This method affords a therapeutic option for the amelioration of 
hyperglycaemia. The action of carbohydrate hydrolyzing enzymes on carbohydrate-containing 
diet has a significant effect on postprandial blood glucose level and delaying the digestion of 
carbohydrate like starch and sucrose will translate into lower postprandial blood glucose (Dhital 
et al., 2013; Reuser and Wisselaar, 1994). α-glucosidase and α-amylase inhibitors have gained 
much popularity as a class of hypoglycaemic agents, which decreases postprandial blood 
glucose via inhibition of the action of α-glucosidase and α-amylase enzymes (Patel et al., 2012). 
Our findings revealed that caffeine did have the ability to inhibit α-amylase and α-glucosidase 
in a non-dose dependent manner, however, the results were significantly lower (p < 0.05) 
compared to acarbose in all concentrations used in this experiment (Figure 3.5 and Figure 
3.6). Lower inhibitory activity of caffeine might be due to very low dose used in our study. 
However, our results are also supported by the results of a recent study (Alongi and Anese, 
2018) where the efficiency of α-glucosidase inhibition by extracts obtained from roasted coffee 
beans was demonstrated.   
Research has demonstrated the potential of natural products to counteract obesity. Natural 
products provide a vast pool of pancreatic lipase inhibitors. Caffeine supplementation has been 





thus plays an effective role in weight management (Heckman et al., 2010). It has been shown 
to increase energy expenditure in humans, and weight loss has reduced risk factors for diabetes 
in clinical trials (Ketzal et al., 1995). Consequently, it seems possible that caffeine consumption 
may decrease diabetes risk by helping individuals control their body weight. This study 
demonstrated a dose-dependent anti-lipase activity of caffeine, the level of inhibitory activities 
was moderate might be due lower concentrations used in our study (Figure 3.7). Reports have 
shown that a wide variety of plant products such as polyphenols, flavonoids, and caffeine 
possess lipase inhibitory effects (Yun, 1010). An in vivo study also showed that caffeine 
stimulates fat breakdown (Mohammed et al., 2014).  
In vitro studies have shown that caffeine, even at millimolar concentrations, shows potent 
antioxidant power by preventing lipid peroxidation (Daniela et al., 2017). These reports have 
suggested that the ability of caffeine to inhibit lipid peroxidation is similar to glutathione and 
significantly greater than that of ascorbic acid. Ferrous sulphate (FeSO4) was used in this study 
to induce lipid peroxidation since the deleterious effects of iron has been earlier explained. 
Incubation of tissue homogenates with FeSO4 has been shown to cause lipid peroxidation (Oboh 
et al., 2007). In this study, the increased MDA level (Figure 3.8) shows an occurrence of Fe2+- 
induced lipid peroxidation in the pancreatic tissues which shows successful induction of 
oxidative injury. The significantly lower (p < 0.05) MDA level in the pancreatic tissues 
indicates the reduction in lipid peroxidation by caffeine (Figure 3.8). Superoxide dismutase 
(SOD) and catalase (CAT) are vital antioxidant enzymes required for the protection against free 
radicals (Dudonne et al., 2009). SOD which is produced primarily in the mitochondria (Genova 
et al., 2001), catalyses the conversion of the superoxide radical to hydrogen peroxide, which is 
then converted to water and oxygen by catalase (Asmat et al., 2016). A significant reduction (p 
< 0.05) in SOD and CAT were observed in the untreated control groups (Figure 3.10 and 
Figure 3.11). The reduction in these enzyme activities could be due to the derangement of the 
three isoenzymes of SOD by Fe2+ undergoing reduction Fe3+ during the Fenton reaction (Sanni 
et al., 2018). The increased activity of SOD and CAT (Figure 3.10 and Figure 3.11) in the 
pancreatic tissue following the treatment of caffeine additionally reveals its antioxidative 
potency. The ability of these extracts to improve endogenous antioxidant status might be due 
to the presence of polyphenols and melanoidins in pure caffeine reported in a study (Metro et 
al. 2017) 
The main dietary source of glucose for human is starchy foods and other comparable 





factor that plays a major role in the advancement of diabetes, obesity and related metabolic 
disorders (Dhital et al., 2013). Glucose is rapidly absorbed in the intestine by a mechanism of 
facilitated diffusion, and results from previous in vitro studies have suggested the elevated 
capacity of glucose absorption across all segments of the small intestine (Fearson and Bird, 
1968), with the proximal-to-mid small intestine (part of the duodenum and jejunum) having the 
highest absorption capacity (Lavin, 1976). In the present study, a 2-hour incubation of isolated 
rat jejunum in a glucose solution with caffeine showed that there was a significant and dose-
dependent reduction (p < 0.05) in the glucose absorption capacity, when the higher inhibition 
of absorption was observed at concentrations of 120 and 240 µg/mL (Figure 3.12). This is an 
indication of the possible inhibitory potentials of caffeine on intestinal glucose absorption, 
which is in line with its observed α-glucosidase and α-amylase enzymes inhibitory activity 
(Figure 3.5 and 3.6). The inhibitory activity of caffeine to these carbohydrate digesting 
enzymes might be partly involved in its mechanism behind the hypoglycaemic effect.  
In T2D, glucose uptake by skeletal muscle is significantly reduced consequently, resulting in 
hyperglycaemia. Therefore, antidiabetic drugs have targeted to improve the glucose uptake as 
their mode of action. In the present study, the dose-dependent increase in muscle glucose uptake 
shown by caffeine, (Figure 3.13) additionally reveals its antidiabetic potentials. This further 
suggesting the potential of caffeine in increasing muscle glucose uptake, which in turn may 
decrease hyperglycaemia in T2D. 
 
The promising in vitro antioxidant and anti-diabetic potentials of caffeine prompted the need to 
examine its antioxidative effects in a type 2 diabetes model of rats. The use of rat models in 
studying diabetes mellitus is well known and a useful method for investigating the protective 
effects of various natural and chemically originated agents on diabetes and its associated 
complications (Yilmaz et al., 2014). A reliable T2D rat model must demonstrate the main 
pathological features of the disease which is insulin resistance as well as partial damage to the 
β-cells of the pancreas. The model used in this study was developed by Wilson and Islam (2012) 
and it successfully induced T2D by showing insulin resistance by feeding 10% fructose solution 
instead of drinking water followed by a low-dose STZ injection, which causes partial pancreatic 
β-cell damage.  
 
Polydipsia, polyphagia and weight loss are some of the most common symptoms of diabetes 





generally dependant on energy expenditure, urinary excretion of glucose and catabolic 
processes among others. Although treatment with caffeine did not completely reverse the T2D 
induced polyphagia, polydipsia and weight loss, improvement of BW in the DCAFH group 
compared to the DC group (Figure 3.15) denotes the body weight ameliorative effect of 
caffeine.  
 
Postprandial hyperglycaemia is a common pathogenesis of T2D which is induced by insulin 
resistance and partial pancreatic beta cell destruction (Wilson and Islam, 2012). Effective 
control of the blood glucose concentration is a vital step in ameliorating complications of 
diabetes and enhancing the quality of life in type 2 diabetic patients (Ross, 2004). In this study, 
oral treatment of the high dose of caffeine (DCAFH) resulted in a significant (p < 0.05) and 
consistent decrease in blood glucose levels (Figure 3.16) throughout the experimental period, 
signifying its potent anti-diabetic activity. Furthermore, the observed better glucose tolerance 
ability in the DCAFH group compared to the DBC group (Figure 3.17) also denotes its glucose 
tolerance improving activity.  
T2D is associated with vast changes in serum lipid and lipoprotein profiles accompanied with 
a high risk of cardiovascular disease (Kumar et al., 2011). Hyperlipidemia is an established 
impediment in diabetic subjects which is characterized by an increased serum cholesterol and 
triglycerides levels (Kumar et al., 2011). This is primarily due to the uncontrolled actions of 
lipolytic hormones on the fat depots resulting from the impairment of insulin secretions in 
diabetic subjects. In this study, serum total and LDL-cholesterols were significantly increased 
(p < 0.05) and triglycerides were relatively increased after the induction of diabetes in rats 
(Figure 3.18). On the other hand, the significantly lower serum total cholesterol concentration 
in the DCAFL group than the untreated control group (Figure 3.18) denotes it hypolipidemic 
activity as well although no significant differences were observed for other groups or other 
lipid-related parameters. This observation is perhaps related to the stimulation of insulin 
secretion by the compound which could modulate the actions of the lipolytic hormones in fat 
reserves. 
An important feature of experimentally induced diabetes is a decrease in the liver glycogen 
level which is caused by the modulation of glycogen synthase and glycogen phosphorylase 
enzymes activities. In our study, feeding high dose of caffeine (DCAFH) significantly 





3.4) might be due to the decreasing glycogen phosphorylase and/or increasing glycogen 
synthase activity caffeine. However, further studies are needed to ascertain this speculation.  
The serum fructosamine level is a measure of early protein glycation which is formed by the 
covalent binding of glucose to serum proteins via a non-enzymatic glycation reaction (Huang 
et al., 2011; Habibuddin et al., 2008).  It shows the overall level of blood glucose in last several 
weeks’ time in a diabetic subject. In our study, the treatment with the high dose of caffeine 
(DCAFH) was found to ameliorate the T2D-induced increase in serum fructosamine level 
(Table 3.5) which again supports the hypoglycemic effects of caffeine. The level of serum 
insulin is usually reciprocal with the level of serum fructosamine in diabetic condition. The 
higher serum insulin levels observed in the high dose-treated (DCAFH) group suggest that 
caffeine has insulin secretagogue activity which has been further proven by calculated HOMA-
IR and HOMA-β scores as discussed below. 
A recent study reported that the patients with T2D have lower insulin secretory capacities with 
mild, but evident, insulin resistance (Urakami et al., 2013). The HOMA-β and HOMA-IR 
scores are used to determine the insulin secreting ability of pancreatic beta-cells or the level of 
pancreatic β-cell function (HOMA-β) and the degree of insulin resistance (HOMA-IR), 
respectively. The significantly higher HOMA-IR scores and significantly lower HOMA-β 
scores in the DBC group compared to the NC group denotes the induction of insulin resistance 
and partial pancreatic β-cell dysfunction in our animal model. On the other hand, the 
significantly lower HOMA-IR scores and significantly higher HOMA- β scores in the DCAFH 
compared to the DBC group (Table 3.5) provide additional evidence that caffeine treatment at 
40 mg/kg BW not only has insulin resistance ameliorative effects but also has pancreatic β-cell 
protecting ability in STZ-induced type 2 diabetic rats. These effects were also comparable with 
the standard anti-diabetic drug (metformin) used in this study (Table 3.5).  
The serum levels of ALP but not AST were significantly increased in the untreated diabetic 
animals (Table 3.6) indicating impaired liver function, which is due to hepatocellular necrosis. 
Diabetic complications such as increased ketogenesis and gluconeogenesis may be due to the 
elevated aminotransferase activities. Thus, restoration of these enzymes towards near normal 
levels specifies decreased diabetic complications in the DACFH and DM treated groups. 
Moreover, the DCAFH group reversed the T2D-induced increase in serum urea level (Table 
3.6) which indicates the amelioration in renal impairment and related complications in diabetes. 
Reports have shown that creatinine is a biomarker for T2D and insulin resistance (Kumar et al., 





centre for the action of insulin and subsequent glucose disposal. Muscle mass directly correlates 
to serum creatinine. Thus, the serum creatinine could be a reliable marker to assess insulin 
resistance (Kumar et al., 2012). Thus, previous studies have demonstrated lower serum 
creatinine level in T2D human patients compared to normal subjects (Hjelmesaeth, 2010; Harita 
et al., 2009) which collaborates with our findings (Table 3.6).  
The anti-oxidative status of the serum and the several organs of the caffeine treated diabetic 
rats were examined to determine, whether or not, the anti-diabetic effects of the caffeine in 
various organs was obtained via improving anti-oxidative status or not. The severity of damage 
resulting in the brain, kidney, heart, liver and pancreatic tissues of the diabetes-induced groups 
were monitored using the TBARS, GSH and catalase assays. STZ causes an increase in ROS 
levels and free radicals, as seen in diabetic subjects, resulting in a huge role in tissue damage 
which is supported by several studies (Bergamini et al., 2004; Forbes et al., 2008; Evans et al., 
2003). 
Apart from above studies, a number of other studies suggest that oxidative stress is involved in 
the etiology of numerous diabetic complications (King & Loeken, 2004; Yilmaz et al., 2004; 
Kakker et al., 1995; Rahman et al., 2007). Oxidative stress in diabetic condition arises from the 
increased production of free radicals and/or diminished endogenous antioxidant activities 
(Piconi et al., 2003). The level of lipid peroxidation (LPO) in physiological system is generally 
measured by the production of LPO end products as MDA equivalent. On the other hand, the 
determination of antioxidant capacity that supports the inhibition of LPO as a mode of action 
of natural antioxidants in diabetic patients (Solomon et al., 2010) is measured by the levels of 
endogenous antioxidant such as reduced glutathione (GSH) and level of antioxidative enzymes 
activity such as catalase, super oxide dismutase, glutathione reductase and glutathione 
peroxidase. The results obtained from this study portrays a significant increase (p<0.05) in 
MDA concentration in all organs and serum samples of the diabetic (DBC group) rats compared 
to normal rats (NC group) (Figure 3.19) confirms the induction of oxidative stress in diabetic 
condition. This increase is known to be evidence of excess free radical production which is 
characteristic of patients with T2DM (Bayir, 2005), owing to elevated oxidative stress. In this 
study, the administration of caffeine at a medium (20 mg/kg b.w) and high dose (40  mg/kg 
b.w.) showed a significant reduction (p<0.05) in the MDA concentration in most organs (brain, 
kidney, liver, pancreas) and serum sample (Figure 3.19) indicating the oxidative stress reducing 





GSH is a non-enzymatic antioxidant that defends oxidative damage which is related to the 
pathogenesis of diabetes and diabetics tend to have very low concentrations of cellular GSH 
(Anthony et al., 2009) and a declined NADPH levels (Maritim et al., 2003). GSH has been 
reported to be one of the most vital scavengers of ROS (Zitka et al., 2012). The level of GSH 
in the liver, pancreas and serum of DBC group was found to be significantly lower than the NC 
group (Figure 3.20). The data obtained from the GSH assay correlates with a study that found 
a decrease in GSH concentrations in the kidney, liver, heart, pancreas and serum of animals that 
were chemically induced with diabetes (Maritim et al., 2003). However, the significantly higher 
GSH concentration in the brain, liver, pancreas and serum of DCAFH group compared to the 
DBC group (Figure 3.20) denotes the antioxidative status improving effects of caffeine diabetic 
condition.  
 
Antioxidative enzymes such as catalase plays a crucial role in eradicating the harmful effects 
of ROS and free radicals towards tissue damages. The reduced activity of antioxidant enzymes 
that is observed in the various tissues of the untreated DBC group could make these specific 
organs vulnerable to oxidative stress (Kakkar et al., 1995). Interestingly, there was a significant 
increase (p<0.05) in the catalase activity of the tissues of animals administered with the medium 
and high dose of caffeine as well as the metformin group (Figure 3.21).  The increased catalase 
activity in the organs and serums of the DCAFM and DCAFH groups suggests an increased 
anti-oxidative activity, indicating a protective effect against H2O2 superoxide radical. This 
effect of caffeine is also comparable with the results obtained for standard anti-diabetic drug 
(metformin) used in this study.  
 
Interestingly, these results were further supported by the histopathological examinations of the 
pancreatic islets where DCAFH groups (Figure 3.22) had more as well as healthier pancreatic 
islets than the DBC group. The DCAFH group was found to have high in vitro anti-oxidative 
activity, suggesting that the protection of the pancreatic islets could be mediated through an 
anti-oxidative dependent mechanism because oxidative stress is an important biological 
phenomenon in the process of pancreatic β-cell damage in T2D. Kagami et al. reported that 
caffeine (100 mg/kg BW) pre-injection can successfully prevent the STZ-induced (65 mg/kg 
BW) pancreatic beta-cell damage in male Wistar rats (Kagami et al., 2008). So, our results are 







In conclusion, our data suggest that caffeine displayed anti-oxidative activities and inhibited 
key enzymes linked to type 2 diabetes which could be exploited for the development of holistic 
therapeutic strategy for the control of postprandial blood glucose levels, T2D and chronic 
vascular complications. The results of this study demonstrate that caffeine can modulate T2D-
induced oxidative stress in various organs and this mechanism plays a vital role in the overall 
anti-T2D effects of the compound. The various mechanisms of action are elicited through 
delaying small intestinal glucose absorption, increasing muscle glucose uptake, improving 
pancreatic β-cell function and stimulating insulin secretions rather than by increasing insulin 
sensitivity. Pancreatic histopathology showed that caffeine prevents T2D-induced pancreatic β-
cell destruction and improves their functions. Considering all above, caffeine can be used an 
effective anti-diabetic supplement in ant-diabetic foods and food products. Further studies are 
still warranted in humans and experimental animals in order to determine the most effective 
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